taurine has been researched along with acamprosate in 511 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (1.57) | 18.7374 |
| 1990's | 82 (16.05) | 18.2507 |
| 2000's | 241 (47.16) | 29.6817 |
| 2010's | 172 (33.66) | 24.3611 |
| 2020's | 8 (1.57) | 2.80 |
| Authors | Studies |
|---|---|
| Bourreille, J; Cardot, F; Fortier-Beaulieu, M; Hemet, J; Moore, N; Noblet, C; Thomine, E | 1 |
| D'Amico, E; Koob, GF; Pulvirenti, L; Rassnick, S; Riley, E; Zieglgänsberger, W | 1 |
| Opsomer, L; Potgieter, AS | 1 |
| Capron, D; Capron, JP; Delgrange, T; Duron, B; Khater, J | 1 |
| Daoust, M; Ernouf, D; Narcisse, G; Poulain, D | 1 |
| Daoust, M; DeWitte, P; Durbin, P; Gewiss, M; Heidbreder, C; Legrand, E; Tran, G | 1 |
| De Witte, P; Durbin, P; Gewiss, M; Heidbreder, C; Opsomer, L | 1 |
| Libert, C; Moore, N | 1 |
| Fourtillan, JB; Girault, J; Gobin, P | 1 |
| Boismare, F; Daoust, M; Ladure, P; Langrenon, S; Lhuintre, JP; Libert, C; Moore, N; Parot, P; Steru, L; Tran, G | 1 |
| Boismare, F; Boucly, P; Chabenat, C; Ladure, P; Moore, N | 1 |
| Grant, KA; Woolverton, WL | 1 |
| Boismare, F; Daoust, M; Flipo, JL; Lhuintre, JP; Moore, N; Saligaut, C | 1 |
| Bosimare, F; Chretien, P; Daoust, M; Hillemand, B; Lhuintre, JP; Moore, ND; Saligaut, C; Tran, G | 1 |
| Andre, D; Boismare, F; Boucly, P; Chabenat, C; Chretien, P; Daoust, M; Lhuintre, JP; Moore, N; Saligaut, C | 1 |
| Durlach, J; Rinjard, P; Smith, GG; Sprince, H | 1 |
| Blanc-Continsouza, D; Boismare, F; Boucly, P; Chabenat, C; Ladure, P | 1 |
| Boismare, F; Chretien, P; Daoust, M; Durlach, J; Lhuintre, JP; Moore, N; Saligaut, C | 1 |
| Bara, M; Durlach, J; Guiet-Bara, A; Pechery, C | 1 |
| Littleton, J | 1 |
| Guelfi, JD; Paille, FM; Parot, P; Perkins, AC; Royer, RJ; Steru, L | 1 |
| Ades, J; Lejoyeux, M | 1 |
| Capogna, M; Kasparov, S; Zeise, ML; Zieglgänsberger, W | 1 |
| Fendl, A; Knecht, T; Ladewig, D; Leher, P | 1 |
| Fischer, F; Fleischhacker, WW; Lesch, OM; Nimmerrichter, A; Oberbauer, H; Platz, T; Potgieter, A; Walter, H; Whitworth, AB | 1 |
| Chick, J | 1 |
| Mann, K; Sass, H; Soyka, M; Zieglgänsberger, W | 1 |
| Mann, K | 2 |
| Lesch, OM; Walter, H | 1 |
| Madamba, SG; Schweitzer, P; Siggins, GR; Zieglgänsberger, W | 1 |
| Schuckit, MA | 1 |
| Allingham, K; Hölter, SM; Landgraf, R; Spanagel, R; Zieglgänsberger, W | 1 |
| Putzke, J; Schöbitz, B; Spanagel, R; Stefferl, A; Zieglgänsberger, W | 1 |
| Hundt, W; Spanagel, R; Zieglgänsberger, W | 1 |
| Allen, J; Fertig, J; Litten, RZ | 1 |
| Lovinger, DM | 1 |
| Litten, RZ | 1 |
| Overstreet, DH | 1 |
| Sass, H; Soyka, M | 1 |
| Putzke, J; Spanagel, R; Tölle, TR; Zieglgänsberger, W | 1 |
| Kotter, G; Preuss, U; Schütz, C; Soyka, M | 1 |
| Spanagel, R; Zieglgänsberger, W | 1 |
| Swift, RM | 1 |
| Wagstaff, AJ; Wilde, MI | 1 |
| Hölter, SM; Landgraf, R; Spanagel, R; Zieglgänsberger, W | 1 |
| Balldin, J; Bendtsen, P; Berglund, M; Borg, S; Franck, J; Gustafsson, L; Halldin, J; Månsson, M; Nilsson, LH; Stolt, G; Willander, A | 1 |
| Gavrilovic, M; Le Bon, O; Lehert, P; Lion, K; Pelc, I; Verbanck, P | 1 |
| Drummond, DC; Moncrieff, J | 1 |
| Pelc, I | 1 |
| Besson, J | 1 |
| Durbin, P; Heyser, CJ; Koob, GF; Schulteis, G | 1 |
| Daly, C; Haddad, P | 1 |
| Berton, F; Francesconi, WG; Madamba, SG; Siggins, GR; Zieglgänsberger, W | 1 |
| Poldrugo, F | 1 |
| Aeby, F; Besson, J; Kasas, A; Lehert, P; Potgieter, A | 1 |
| Caspary, A; Emrich, HM; Haacker, T; Schneider, U; Schulze-Bonhage, A; Wohlfahrt, K; Zedler, M | 1 |
| Daoust, M; Durbin, P; Hammoumi, S; Legrand, E; Naassila, M | 1 |
| al Qatari, M; Bouchenafa, O; Littleton, J | 1 |
| Wickelgren, I | 1 |
| Bolo, N; Dahchour, A; De Witte, P; Durbin, P; Macher, JP; Muzet, M; Nédélec, JF | 2 |
| Kratzer, U; Schmidt, WJ | 2 |
| Allen, JP; Litten, RZ | 2 |
| Corrigall, WA; Shaham, Y; Sillaber, I; Spanagel, R; Stewart, J; Zieglgänsberger, W | 1 |
| Gache, P; Siegrist, G | 1 |
| Chabac, S; Durbin, P; Houin, G; Hulot, T; Potgieter, A; Saivin, S | 1 |
| Bonn, D | 1 |
| Aichmüller, C; Möller, HJ; Preuss, U; Soyka, M | 1 |
| Becker, H; Dengler, R; Emrich, HM; Haacker, T; Müller-Vahl, KR; Schneider, U; Schulze-Bonhage, A; Wohlfarth, K; Zedler, M | 1 |
| Brecht, JG; Schädlich, PK | 1 |
| Soyka, M; Zieglgänsberger, W | 1 |
| Carey, TS; Crews, FT; Garbutt, JC; Lohr, KN; West, SL | 1 |
| Malerich, JA | 1 |
| Rueff, B | 1 |
| Dahchour, A; De Witte, P | 3 |
| Mason, B | 1 |
| Kornhuber, J; Spanagel, R | 1 |
| Baghai, T; Laakmann, G; Neukam, C; Schüle, C; Soyka, M | 1 |
| Farren, CK; O'Malley, SS | 1 |
| Bosc, N; Fabre, H; Perrin, C | 1 |
| Cioli, I; Duprè, S; Nencini, P; Pascucci, T; Pisetzky, F; Spirito, A | 1 |
| Cole, JC; Little, HJ; Littleton, JM | 1 |
| Fiellin, DA; O'Connor, PG; Reid, MC | 1 |
| Foster, RH; McClellan, KJ | 1 |
| Lovinger, DM; Popp, RL | 1 |
| Ait-Daoud, N; Johnson, BA | 2 |
| Annemans, L; D'Hooghe, D; Tecco, J; Vanoverbeke, N | 1 |
| Hölter, SM; Spanagel, R | 1 |
| Oberpichler-Schwenk, H | 1 |
| Koob, GF | 1 |
| Ansoms, C; Deckers, F; Lehert, P; Pelc, I; Potgieter, A | 1 |
| Engelhard, K; Kochs, E; Lu, H; Möllenberg, O; Werner, C; Zieglgänsberger, W | 1 |
| Dengler, R; Emrich, HM; Haacker, T; Rollnik, JD; Schneider, U; Schubert, M; Schulze-Bonhage, A; Wohlfarth, K; Zedler, M | 1 |
| Allgaier, C; Franke, H; Scheibler, P; Sobottka, H | 1 |
| Kalb, C | 1 |
| Brady, KT; Malcolm, R; Myrick, H | 1 |
| Czachowski, CL; Legg, BH; Samson, HH | 1 |
| Mackler, SA; O'Brien, CP; Stromberg, MF; Volpicelli, JR | 1 |
| Mahal, B; Parsons, C; Pestel, E; Putzke, J; Rammes, G; Schadrack, J; Spanagel, R; Spielmanns, P; Zieglgänsberger, W | 1 |
| Boening, JA; Lesch, OM; Mason, BJ; Narita, M; Sinclair, D; Spanagel, R; Wiesbeck, GA; Wolffgramm, J | 1 |
| Aistrup, GL; Engel, JA; Ericson, M; Hedlund, L; Kalouti, U; Marszalec, W; Narahashi, T; Nordberg, A; Olausson, P; Schmidt, LG; Smolka And, M; Söderpalm, B; Zhang, X | 1 |
| Tedeschi, M | 1 |
| Bean, P; Mattson, M | 1 |
| Carey, TS; Crews, FT; Garbutt, JC; Jackman, AM; Lohr, KN; Lux, LJ; Tolleson-Rinehart, S; West, SL | 1 |
| Gordon, SM | 1 |
| Daniel, D; Kilburg, A; Kirchhoff, D; Paschen, B; Pfeil, T; Rychlik, R | 1 |
| Korpi, E; Seppälä, T | 1 |
| al Qatari, M; Harris, B; Khan, S; Littleton, J | 1 |
| Kranzler, HR; Van Kirk, J | 1 |
| Anton, RF | 1 |
| Mason, BJ | 5 |
| Yarborough, WH | 1 |
| Chester, JA; Froehlich, JC; Grahame, NJ; Li, TK; Lumeng, L | 1 |
| Kaminska, E; Kus, K; Midolajczak, P; Okulicz-Kozaryn, I; Szczawinska, K | 1 |
| Arlinde, C; Heilig, M; Rimondini, R; Sommer, W | 1 |
| Ball, D; De Witte, P; Marshall, EJ; Martinez, J; Ward, RJ | 1 |
| Hodge, CW; Koenig, HN; Nannini, MA; Olive, MF; Ou, CJ | 1 |
| Preuss, U; Schuetz, C; Soyka, M | 1 |
| Chen, YJ; Ge, FG; Qiu, LY; Wang, DB | 1 |
| Le, AD; McBride, WJ; Noronha, A | 1 |
| De Witte, P; Koob, GF; Littleton, J; Mason, BJ; Siggins, GR | 1 |
| Fuchs, WJ; Riebenfeld, D | 1 |
| Blanchard, J; Gibson, DA; Harris, B; Holley, RC; Littleton, J; Mayer, S; Prendergast, MA | 1 |
| Contreras, E; Ortega, A; Sepúlveda, J; Zapata, G | 1 |
| Fideli, LP; Lejoyeux, M | 1 |
| Graham, R; Whelan, G; Wodak, AD | 1 |
| Gebka, J; Kaminska, E; Mikolajczak, P; Niedopad, L; Okulicz-Kozaryn, I; Polanska, A | 1 |
| Connor, JP; Feeney, GF; McPherson, A; Tucker, J; Young, RM | 1 |
| Granero, L; Guerri, C; Polache, A; Zornoza, T | 1 |
| Brabant, C; De Witte, P; Quertemont, E | 1 |
| Boyeson, MG; Dixon, RM; Goodman, AM; Hameed, MH; Hulot, T; Hunter, JA; Mason, BJ; Wesnes, K | 1 |
| Blanchard, JA; Gibson, DA; Harris, BR; Holley, RC; Littleton, J; Mayer, S; Prendergast, MA | 1 |
| Ansoms, C; Fischer, F; Fuchs, WJ; Landron, F; Lehert, P; Morgan, MY; Pelc, I; Pires Preto, AJ | 1 |
| Olive, MF | 3 |
| Blanchard, JA; Fu, MC; Gibson, DA; Harris, BR; Hart, SR; Holley, RC; Littleton, JM; Pedigo, NW; Prendergast, MA; Rogers, DT | 1 |
| Baehr, M; Briken, P; Helwig, H; Holzbach, R; Jahn, H; Kämpf, P; Kiefer, F; Naber, D; Stracke, R; Tarnaske, T; Wiedemann, K | 1 |
| McGeehan, AJ; Olive, MF | 2 |
| Cano-Cebrián, MJ; Granero, L; Guerri, C; Polache, A; Zornoza-Sabina, T | 2 |
| Daniel, D; Pfeil, T; Rychlik, R; Siedentop, H | 1 |
| Heyser, CJ; Koob, GF; Moc, K | 1 |
| Bransberger, P; Crosse, S; Kranzler, HR; Mark, TL; Poole, VH; Song, X | 1 |
| Niederhofer, H; Staffen, W | 1 |
| Chambers, RA; Ciraulo, DA; Couper, D; Johnson, BA; O'Malley, SS; Roache, JD; Sarid-Segal, O | 1 |
| Kratzer, U; Schmidt, WJ; Spanagel, R | 1 |
| Feeney, A; Feldtkeller, B; Lingford-Hughes, A; Nutt, D; Weinstein, A | 1 |
| O'Brien, CP | 3 |
| Doran, CM; Fawcett, JE; Mattick, RP; Shakeshaft, AP; Shanahan, MD | 1 |
| Farkas, S; Horváth, C; Kolok, S; Nagy, J; Szombathelyi, Z | 1 |
| Baltieri, DA; de Andrade, AG | 2 |
| Kiefer, F; Mann, K; Smolka, MN | 2 |
| Cano, MJ; Granero, L; Polache, A; Zornoza, T | 1 |
| Han, BD; Kim, MJ; Kim, SG; Park, JM; Stromberg, MF | 1 |
| Lehert, P; Mann, K; Morgan, MY | 1 |
| Landron, F; Lehert, P; Morgan, MY | 1 |
| Hyytiä, P; Kiianmaa, K; Tiihonen, J | 1 |
| Salaspuro, M | 1 |
| Chick, J; Landron, F; Lehert, P | 1 |
| Littleton, J; Zieglgänsberger, W | 1 |
| Anton, RF; Swift, RM | 1 |
| Chick, J; Soyka, M | 1 |
| Cador, M; Koob, GF; Stinus, L; Zorrilla, EP | 1 |
| Daoust, M; Naassila, M; Pierrefiche, O | 1 |
| Boeijinga, PH; Danel, T; Demazières, A; Gendre, I; Landron, F; Luthringer, R; Muzet, M; Parot, P; Soufflet, L | 1 |
| Holsboer, F; Koller, G; Soyka, M; Spring, K; Zimmerman, U | 1 |
| Amate, JM; Angeles, M; Bouza, C; Magro, A; Muñoz, A | 1 |
| Cornelissen, B; Courtyn, J; Oltenfreiter, R; Slegers, G; Strijckmans, K; Vandecapelle, M | 1 |
| Bespalov, A; Danysz, W; Kashkin, V; Malyshkin, A; Neznanova, O; Sukhotina, I; Zakharova, E | 1 |
| Brasser, SM; Houtsmuller, EJ; McCaul, ME | 1 |
| Cano-Cebrián, MJ; Granero, L; Guerri, C; Nalda-Molina, R; Polache, A; Zornoza, T | 1 |
| Geerlings, PJ; Koeter, MW; Lehert, P; van den Brink, W; Verheul, R | 1 |
| Anton, R; Myrick, H | 1 |
| Mann, K; Spanagel, R | 1 |
| Biala, G; Bochenski, M; Danysz, W; Kotlinska, J; Rafalski, P | 1 |
| Lee, TH | 1 |
| Kenna, GA; McGeary, JE; Swift, RM | 1 |
| Abarca, C; Albrecht, U; Depner, M; Holzberg, D; Lascorz, J; Lathrop, M; Magnone, MC; Matsuda, F; Pendyala, G; Sanchis-Segura, C; Schreiber, S; Schumann, G; Soyka, M; Spanagel, R; Zghoul, T | 1 |
| Adde-Michel, C; Hennebert, O; Laudenbach, V; Leroux, P; Marret, S | 1 |
| Herzig, V; Schmidt, WJ | 2 |
| Bachteler, D; Ciccocioppo, R; Danysz, W; Economidou, D; Spanagel, R | 1 |
| Baltieri, DA; Castro, LA | 1 |
| Helwig, H; Jahn, H; Kiefer, F; Otte, C; Tarnaske, T; Wiedemann, K | 1 |
| Kaminska, E; Mikolajczak, P; Okulicz-Kozaryn, I; Piorunska-Mikolajczak, A; Piorunska-Stolzmann, M | 1 |
| Figgitt, DP; Keam, SJ; Scott, LJ; Waugh, J | 1 |
| De Witte, P; Koob, G; Littleton, J; Parot, P | 1 |
| Demiralay, C; Jahn, H; Kiefer, F; Otte, C; Wiedemann, K; Wolf, K | 1 |
| Cwiek, W; Czarnecka, E; Dyr, W; Zalewska-Kaszubska, J | 1 |
| Jahn, H; Kiefer, F; Wiedemann, K | 1 |
| Adams, C; Cowen, MS; Kraehenbuehl, T; Lawrence, AJ; Vengeliene, V | 1 |
| Boothby, LA; Doering, PL | 1 |
| Dahchour, A; De Witte, P; Lallemand, F; Ward, RJ | 1 |
| Berglund, M; Johnson, BA; Lesch, OM; Litten, RZ; Mann, K; Swift, RM; Willenbring, ML | 1 |
| Litten, RZ; Mattson, ME | 1 |
| Anton, R; Goldman, D; O'Malley, S; Oroszi, G | 1 |
| Pettinati, HM; Swift, R | 1 |
| Ait-Daoud, N; Johnson, BA; Roache, JD | 1 |
| Buonopane, A; Petrakis, IL | 1 |
| Williams, SH | 1 |
| Egli, M | 1 |
| Bochenski, M; Danysz, W; Kotlinska, J | 1 |
| Sher, L | 1 |
| Haber, PS; Matsuda, M; Reid, SC; Sannibale, C; Teesson, M | 1 |
| Hussar, DA | 1 |
| Jahn, H; Kiefer, F; Naber, D; Otte, C; Wiedemann, K | 1 |
| Beilby, JJ; Doran, CM; Duszynski, KM; Mattick, RP | 1 |
| Egli, M; Heilig, M | 1 |
| Chabac, S; Goodman, AM; Lehert, P; Mason, BJ | 1 |
| Croissant, B; Diehl, A; Heinz, A; Klein, O; Mann, K; Nakovics, H; Zambrano, S | 1 |
| Jung, YC; Namkoong, K | 1 |
| Anton, RF; Ciraulo, DA; Cisler, RA; Couper, D; Donovan, DM; Gastfriend, DR; Hosking, JD; Johnson, BA; LoCastro, JS; Longabaugh, R; Mason, BJ; Mattson, ME; Miller, WR; O'Malley, SS; Pettinati, HM; Randall, CL; Swift, R; Weiss, RD; Williams, LD; Zweben, A | 1 |
| Leeman, RF; Starosta, AN; Volpicelli, JR | 1 |
| Chawla, PS; Kochar, MS | 1 |
| Escher, T; Mittleman, G | 1 |
| Jahn, H; Kiefer, F; Nakovics, H; Otte, C; Wiedemann, K | 1 |
| Cano-Cebrián, MJ; Granero, L; Hipólito, L; Polache, A; Zornoza, T | 1 |
| Balester-Mouret, S; Batel, P | 1 |
| Borges, S; Flockhart, D; Preskorn, SH | 1 |
| Boeijinga, P; Danel, T; Gendre, I; Landron, F; Luthringer, R; Muzet, M; Staner, L | 1 |
| Bell, JR; Haber, PS; Morley, KC; Phung, N; Reid, SC; Richardson, K; Sannibale, C; Teesson, M; Thomson, C; Weltman, M | 1 |
| Pettinati, HM; Rabinowitz, AR | 1 |
| Kranzler, HR | 1 |
| Doggrell, SA | 1 |
| Bleich, S; Hillemacher, T; Kornhuber, J | 1 |
| Connor, JP; Feeney, GF; McD Young, R; McPherson, A; Tucker, J | 1 |
| Füllgrabe, MW; Spanagel, R; Vengeliene, V | 1 |
| Roesner, S; Soyka, M | 1 |
| Ducharme, LJ; Knudsen, HK; Roman, PM | 1 |
| Diehl, A; Mann, K | 1 |
| Mørland, J | 1 |
| Baer, JS; Forcehimes, AA; Kenna, GA; Miller, WR; Tonigan, JS | 1 |
| Coyle, JT | 1 |
| Quertemont, E; Tambour, S | 1 |
| Bray, JW; Cisler, RA; Couper, DJ; Kivlahan, DR; Martin, DJ; Miller, WR; Mitra, D; Zarkin, GA | 1 |
| Howland, RH | 1 |
| Swift, R | 1 |
| Peterson, AM | 1 |
| McDonough, KP | 1 |
| Brunette, MF; Drake, RE; Green, AI; Noordsy, DL | 1 |
| Lawrence, AJ | 1 |
| Altschuler, EL; Kast, RE | 1 |
| Koeter, MW; Ooteman, W; Schippers, GM; van den Brink, W; Verheul, R | 1 |
| Bankes, L; Brown, TM; Guzik, P | 1 |
| Andreoli, M; Ashby, CR; Gardner, EL; Heidbreder, CA; Hutcheson, DM; Marcon, C | 1 |
| Diehl, A; Jiménez-Arriero, MA; Kiefer, F; Klein, O; Rubio, G | 1 |
| Brunette, MF; Green, AI; Noordsy, DL; O'Keefe, C | 1 |
| Bonci, A; Bowers, MS; Chen, BT; Chou, JK; Gass, JT; Janak, PH; Olive, MF; Osborne, MP; See, RE | 1 |
| Johnson, BA | 1 |
| Azevedo, AA; Figueiredo, RR | 1 |
| Han, DH; Lee, SH; Lyool, IK; Renshaw, PF; Sung, YH | 1 |
| Crean, R; Mason, BJ | 1 |
| Kuehn, BM | 1 |
| Spangler, JG | 1 |
| Anton, RF; Donovan, DM; Hosking, JD; Longabaugh, R; Miller, WR; Youngblood, M | 1 |
| Margaron, H | 1 |
| Connor, JP; Feeney, GF; Symons, M; Wiles, J; Young, RM | 1 |
| Czarnecka, E; Dyr, W; Górska, D; Zalewska-Kaszubska, J | 1 |
| Lehert, P; Leucht, S; Rösner, S; Soyka, M | 1 |
| Borghese, CM; Gong, D; Harris, RA; Horishita, T; Lobo, IA; McCracken, LM; Reilly, MT | 1 |
| Anton, RF; Couper, D; Goldman, D; O'Malley, S; Oroszi, G; Pettinati, H; Swift, R | 1 |
| Burattini, C; Gass, JT; Griffin, WC; Janak, PH; Kinder, JR; McGeehan, AJ; Olive, MF | 1 |
| Berglund, M; Gorelick, D; Hesselbrock, V; Johnson, BA; Kranzler, HR; Möller, HJ; Soyka, M | 1 |
| Blanc, F; Perney, P; Rigole, H | 1 |
| Shea, CW | 1 |
| Blednov, YA; Harris, RA | 1 |
| Giménez-Llort, L; Guitart-Masip, M; Hassankhali, H; Johansson, B; Landgren, S; Lindholm, J; Nicoleau, C; Ogren, SO; Terenius, L | 1 |
| Baillie, A; Haber, P; Morley, K; Reid, S; Richardson, K; Sannibale, C; Teesson, M; Weltman, M | 1 |
| Kiefer, F; Littleton, J; Mann, K; Spanagel, R | 1 |
| Jeon, JW; Lee, DS; Lee, TW; Nam, TY; Oh, TO; Park, CW; Park, ES; Park, S; Rhee, YS | 1 |
| Barron, S; Farook, JM; Krazem, A; Lewis, B; Littleton, JM; Morrell, DJ | 1 |
| Bowers, TG; Snyder, JL | 1 |
| Ciraulo, D; Cox, CE; Gorroochurn, P; Mattson, ME; Pettinati, HM; Weiss, RD; Youngblood, M; Zweben, A | 1 |
| Atzori, M; Paz, RD; Tardito, S; Tseng, KY | 1 |
| Abernathy, KE; Bartlett, SE; Chandler, LJ; Medina, B; Simms, JA; Steensland, P; Wise, R | 1 |
| Behm, DJ; Carballo, LH; Dodson, JW; Douglas, SA; Dowdell, SE; Goodman, KB; Hilfiker, MA; McAtee, JJ; Neeb, MJ; Sehon, CA; Viet, AQ; Wang, GZ; Wu, Z; Zhang, D | 1 |
| Soyka, M | 1 |
| Brzezinska, WJ; Cohn, KA; Demeyer, MR; Gupta, T; Martinez, M; Miller, SA; Patel, KY; Revis, AA; Rhodes, JS; Syed, YM | 1 |
| Ha, JM; Jeong, KW; Lee, DS; Park, CW; Park, ES; Park, JH; Park, S; Rhee, YS | 1 |
| Srihari, V; Tek, C; Tek, E | 1 |
| Kassed, CA; Kranzler, HR; Levit, KR; Mark, TL; Vandivort-Warren, R | 1 |
| Bochenski, M; Kotlinska, J | 1 |
| Aldridge, A; Bray, JW; Cisler, RA; Couper, DJ; Mills, MJ; Mitra, D; Zarkin, GA | 1 |
| Hosking, JD; Locastro, JS; O'malley, SS; Swift, R; Weiss, RD | 1 |
| Garbutt, JC | 1 |
| Diehl, A; Herre, H; Kiefer, F; Mann, K; Mutschler, J; Vollmert, C | 1 |
| Czachowski, CL; Delory, MJ | 1 |
| Gann, H; Heinz, A; Kiefer, F; Mann, K; Smolka, M; Wellek, S | 1 |
| Boakes, R; Colagiuri, B; Haber, P; Morley, K | 1 |
| Beck, O; Franck, J; Hammarberg, A; Jayaram-Lindström, N; Reid, MS | 1 |
| Chand, PK; Thirthalli, J | 1 |
| Bilbao, A; Kiefer, F; Pawlak, CR; Perreau-Lenz, S; Spanagel, R; Vengeliene, V; von der Goltz, C | 1 |
| Kenna, GA; Leggio, L; Ray, LA; Swift, RM | 1 |
| Daoust, M; Houchi, H; Koeter, MW; Naassila, M; Ooteman, W; Schippers, GM; van den Brink, W; Verheul, R | 1 |
| Rösner, S; Soyka, M | 2 |
| de Silva, V; Hanwella, R | 1 |
| Oslin, DW; Ray, LA | 1 |
| Franck, J; Hammarberg, A; Jayaram-Lindström, N; Nylander, I; Reid, MS; Zhou, Q | 1 |
| Chau, P; Ericson, M; Höifödt-Lidö, H; Löf, E; Söderpalm, B | 1 |
| Chau, P; Ericson, M; Fagerberg, A; Söderpalm, B; Stomberg, R | 1 |
| Couper, D; Donovan, D; Gueorguieva, R; Krystal, JH; O'Malley, SS; Rounsaville, BJ; Wu, R | 3 |
| Heyser, CJ; Mason, BJ | 2 |
| Liang, M; Qing, Y; Shang, B; Xu, F; Xu, G; Zou, Y | 1 |
| Abraham, AJ; Knudsen, HK; Roman, PM; Rothrauff, TC | 1 |
| Carnahan, RM; Kennedy, WK; Kutscher, EC; Leloux, M; Morstad, AE; Price, PL | 1 |
| Erickson, CA; McDougle, CJ; Mullett, JE | 1 |
| Bray, JW; Dunlap, LJ; Kivlahan, DR; Latham, P; McKay, JR; Mills, M; Tonigan, JS; Zarkin, GA | 1 |
| Bowe, T; Harris, AH; Humphreys, KN; Kivlahan, DR | 1 |
| Aldridge, A; Bray, JW; Cisler, RA; Couper, D; McKay, JR; Mills, M; O'Malley, S; Zarkin, GA | 1 |
| Kiefer, F; Mann, K | 1 |
| Batra, A; Berner, M; Cichon, S; Frank, J; Heinz, A; Kiefer, F; Lemenager, T; Mann, K; Nöthen, MM; Richter, A; Rietschel, M; Smolka, MN; Spanagel, R; Treutlein, J; Wiedemann, K; Witt, SH; Wodarz, N; Zimmermann, US | 1 |
| Andersson, M; Beck, O; Brundin, L; Eksborg, S; Franck, J; Hammarberg, A; Jayaram-Lindström, N; Lindefeldt, A; Reid, MS | 1 |
| Grosshans, M; Kiefer, F; Kobiella, A; Mutschler, J | 1 |
| Koeter, MW; Lehert, P; van den Brink, W | 1 |
| Greenfield, SF; O'Malley, S; Pettinati, HM; Randall, CL; Randall, PK | 1 |
| Leonardi-Essmann, F; Marston, HM; Sommer, WH; Spanagel, R; Vengeliene, V | 1 |
| Falk, D; Fertig, J; Johnson, B; Litten, RZ; Liu, L; Mattson, M; Ryan, M; Stout, R; Wang, XQ | 1 |
| Hackl-Herrwerth, A; Lehert, P; Leucht, S; Rösner, S; Soyka, M; Vecchi, S | 1 |
| Bal, R; Calişkan, AM; Calişkan, S; Naziroğlu, M; Ovey, IS; Ozcankaya, R; Sütçü, R; Uğuz, AC | 1 |
| Adams, LJ; Doty, L; George, DT; Heilig, M; Hommer, D; Lifshitz, M; Momenan, R; Schwandt, ML; Shen, J; Singley, E; Spanagel, R; Umhau, JC; Vengeliene, V; Zhang, Y | 1 |
| Raj, YP | 1 |
| Longabaugh, R; O'Malley, SS; Wirtz, PW; Zywiak, WH | 1 |
| Costello, A; Raza, S; Schwartz, TL; Siddiqui, UA | 1 |
| Guerdjikova, AI; Hudson, JI; Keck, PE; McCoy, J; McElroy, SL; Mori, N; O'Melia, AM; Winstanley, EL | 1 |
| Dackis, C; Kampman, KM; Lynch, KG; O'Brien, CP; Pettinati, HM; Sparkman, T | 1 |
| Capone, C; Kahler, CW; O'Malley, SS; Swift, RM | 1 |
| Choi, DS; Hinton, DJ; Lee, MR; Macura, SI; Mishra, PK; Port, JD; Wu, J | 1 |
| Becker, U; Bendtsen, F; Zierau, F | 1 |
| Bowen, S; Donovan, DM; Witkiewitz, K | 1 |
| George, DT; Geyer, C; Heilig, M; Schwandt, ML; Singley, E; Umhau, JC; Usala, J | 1 |
| Chakraborty, BS; Ghosh, C; Jha, V; Shinde, CP | 1 |
| Frommann, N; Gaebel, W; Kuhlmann, T; Lieb, B; Scherbaum, N; Schifano, F; Specka, M; Wobrock, T | 1 |
| Chalk, M; Gastfriend, DR; Kranzler, HR; Mark, TL; Montejano, LB | 1 |
| Alam, DA; Martorana, A | 1 |
| Abraham, AJ; Knudsen, HK; Roman, PM | 1 |
| Cayley, WE | 1 |
| Donovan, D; Hartzler, B; Villarroel, N; Witkiewitz, K | 1 |
| Bholat, Y; Farrokhi, C; Lacayo, LM; Manalo, CM; Pechnick, RN; Reyes, KC; Spivak, I; Vit, JP | 1 |
| Burtscheidt, W; Falkai, P; Franke, PE; Frommann, N; Gaebel, W; Jänner, M; Kuhlmann, T; Lieb, B; Maier, W; Ohmann, C; Radermacher, M; Scherbaum, N; Schütz, C; Wobrock, T; Wölwer, W | 1 |
| Brady, KT; Brown, DG; Prisciandaro, JJ; Tolliver, BK | 1 |
| Brager, A; Glass, JD; Prosser, RA | 1 |
| Dean, E; Dwan, R; Jane, JS; O'Brien, E; Petrakis, I; Ralevski, E | 1 |
| Baser, O; Chalk, M; Gastfriend, DR; Rawson, R | 1 |
| Campanella, S; Kornreich, C; Noel, X; Petit, G; Verbanck, P | 1 |
| Lehert, P; Mason, BJ | 1 |
| Duhig, A; Mohapatra, S; Patra, J; Popova, S; Rehm, J | 1 |
| Godinho, A; Mohapatra, S; Patra, J; Popova, S; Rehm, J; Schwappach, D | 1 |
| Brager, AJ; Glass, JD; Prosser, RA | 1 |
| Brady, KT; Brown, DG; Chiuzan, C; DeSantis, SM; Prisciandaro, JJ; Tolliver, BK | 1 |
| Ericson, M; Lidö, HH; Marston, H; Söderpalm, B | 1 |
| Lumbad, J; Yancey, JR | 1 |
| Allen, J; Black, DW; Burke, WJ; McNeilly, DP; Shaw, MC | 1 |
| Cesario, A; Leung, YK; Munschauer, FE; Pankewycz, O; Rittenhouse-Olson, K; Sobel, RA; Sternberg, DS; Sternberg, Z; Whitcomb, T; Zhu, B | 1 |
| Krogh, J; Nordentoft, M; Petrov, I | 1 |
| Early, M; Erickson, CA; McDougle, CJ; Mullett, JE; Stigler, KA; Wink, LK | 1 |
| Bujarski, S; Courtney, KE; Ray, LA; Squeglia, LM | 1 |
| Hunter-Reel, D; Witkiewitz, K; Zweben, A | 1 |
| Brady, KT; Brown, DG; Desantis, SM; Prisciandaro, JJ; Tolliver, BK | 1 |
| Doran, CM; Navarro, HJ; Petrie, DJ; Shakeshaft, A | 1 |
| Spanagel, R; Vengeliene, V | 1 |
| Book, SW; Miller, PM; Stewart, SH | 1 |
| Chakraborty, BS; Ghosh, C; Shinde, CP | 1 |
| Chen, J; Isaac, M; Johnson, BA; Liu, L; O'Quigley, J; Wang, XQ; Zhang, D | 1 |
| Fucito, LM; Gueorguieva, RV; Gulliver, SB; Mattson, ME; O'Malley, SS; Park, A | 1 |
| Bandyopadhyay, D; DeSantis, SM; Prisciandaro, JJ | 1 |
| Choi, DS; Frye, MA; Hinton, DJ; Jacobson, TL; Lee, MR; Macura, SI; Mishra, PK; Mrazek, DA | 1 |
| Pałucha-Poniewiera, A; Pilc, A | 1 |
| Clark, DB | 1 |
| Bühler, KM; Echeverry-Alzate, V; Giné, E; Gorriti, MÁ; Huertas, E; López-Moreno, JA; Olmos, P; Rodríguez de Fonseca, F; Santos, Á; Tuda-Arízcun, M | 1 |
| Gahr, M; Kölle, MA; Schönfeldt-Lecuona, C | 1 |
| Feige, B; Hennig, J; Jahnke, K; Kiemen, A; Langosch, JM; Olbrich, HM; Regen, W; Spiegelhalder, K | 1 |
| Blodgett, JC; Finney, JW; Humphreys, K; Maisel, NC; Wilbourne, PL | 1 |
| Baer, L; Bentley, K; Clain, AJ; Evins, AE; Fava, M; Mischoulon, D; Pedrelli, P; Witte, J | 1 |
| Beier, N; Berger, L; Bohn, M; Brondino, M; Fisher, M; Ford, A; Garbutt, JC; Greco, J; Gwyther, R; Longo, L | 1 |
| Anton, RF; Batra, A; Berner, M; Heinz, A; Hermann, D; Hoffmann, S; Kiefer, F; Lemenager, T; Mann, K; Reinhard, I; Smolka, MN; Wellek, S; Wodarz, N; Zimmermann, US | 1 |
| Bujarski, S; Lunny, K; O'Malley, SS; Ray, LA | 1 |
| Kuźniar-Placek, J; Panasiuk, L; Szponar, J | 1 |
| Kalk, NJ; Lingford-Hughes, AR | 1 |
| Bowe, T; Ellerbe, L; Gordon, AJ; Hagedorn, H; Harris, AHS; Kivlahan, D; Lembke, A; Oliva, E; Reeder, RN; Trafton, JA | 1 |
| Choi, IG; Kang, TC; Kim, JW; Lee, BC | 1 |
| Donovan, D; Gueorguieva, R; Krystal, JH; O'Malley, SS; Wu, R | 1 |
| Early, MC; Erickson, CA; Lahiri, DK; Mathieu-Frasier, L; McDougle, CJ; Patrick, V; Ray, B; Stiegelmeyer, E; Wink, LK | 1 |
| Anton, RF; Baker, NL; Bandyopadhyay, D; DeSantis, SM; Prisciandaro, JJ; Randall, PK | 1 |
| O'Connor, PG; O'Malley, SS | 1 |
| Krishnan-Sarin, S; Krystal, JH; O'Malley, S | 1 |
| Gibula-Bruzda, E; Koltunowska, D; Kotlinska, JH | 1 |
| Franck, J; Jayaram-Lindström, N | 1 |
| Falk, D; Fertig, J; Litten, RZ; Ryan, M | 1 |
| Castle, IJ; Chen, CM; Falk, D; Fertig, J; Litten, RZ; Ryan, M; Yi, HY | 1 |
| Higashioka, M; Hirouchi, M; Kurokawa, K; Mizuno, K; Ohkuma, S; Oka, M; Shibasaki, M | 1 |
| Kolik, LG; Kozhechkin, SN; Mednikova, IuS | 1 |
| Hirouchi, M; Oka, M; Oyama, T; Sugahara, S; Tamura, M | 1 |
| Early, MC; Erickson, CA; Mathieu-Frasier, L; McDougle, CJ; Patrick, V; Stiegelmeyer, E; Wink, LK | 1 |
| Fischer, WN; Gallop, MA; Grindstaff, K; Jandeleit, B; Kiefer, F; Krstew, EV; Lawrence, AJ; Spanagel, R; Vengeliene, V; Zhang, X | 1 |
| Bouzegaou, R; Daeppen, JB; Kraemer, KL | 1 |
| Heinz, A; Müller, CA | 1 |
| Heilig, M | 1 |
| Kranzler, HR; Zindel, LR | 1 |
| Knudsen, HK; Roman, PM | 2 |
| Amick, HR; Bobashev, G; Feltner, C; Garbutt, JC; Gass, CE; Jonas, DE; Kim, MM; Rowe, CJ; Shanahan, E; Thomas, K; Wines, R | 1 |
| DeSantis, SM; Zhu, H | 1 |
| Hirouchi, M; Ohhara, T; Oka, M | 1 |
| Liang, J; Olsen, RW | 1 |
| Braciszewski, JM; Falk, D; Kranzler, HR; O'Malley, SS; Stout, RL; Subbaraman, MS | 1 |
| Kufahl, PR; Olive, MF; Watterson, LR | 1 |
| Friedmann, PD; Park, TW | 1 |
| Oetzel, S | 1 |
| Abulseoud, OA; Biernacka, JM; Choi, DS; Cunningham, JM; Frank, J; Frye, MA; Geske, JR; Hall-Flavin, DK; Jenkins, GD; Karpyak, VM; Kiefer, F; Kononenko, O; Leontovich, AA; Loukianova, LL; Mann, KF; Nöthen, MM; Rietschel, M; Rüegg, J; Schneekloth, TD; Skime, MK; Weinshilboum, RM | 1 |
| Bowers, K; Erickson, CA; Lahiri, DK; Maloney, B; McDougle, CJ; Ray, B; Schaefer, TL; Sokol, DK; Wink, LK | 1 |
| Anton, RF; Book, SW; Schacht, JP | 1 |
| Goutier, W; Kloeze, M; McCreary, AC | 1 |
| Fucito, LM; Gueorguieva, R; Hoffmann, S; Mann, K; O'Connor, PG; O'Malley, SS; Weisner, C; Wu, R | 1 |
| Borro, P; Leone, S; Testino, G | 2 |
| Bacciardi, S; Dell'Osso, L; Gazzarrini, D; Icro Maremmani, AG; Maremmani, I; Massimetti, E; Rovai, L; Rugani, F | 1 |
| Bertrand, V; Boucard, A; Callizot, N; Cholet, N; Chumakov, I; Cohen, D; Foucquier, J; Graudens, E; Guedj, M; Hajj, R; Maurice, T; Milet, A; Nabirotchkin, S; Pereira, Y; Scart-Grès, C; Steinschneider, R; Toulorge, D; Traoré, S; Vial, E | 1 |
| Hagerman, RJ; Polussa, J | 1 |
| Amato, RJ; Hulin, MW; Lawrence, MN; Weed, PF; Winsauer, PJ | 1 |
| Donoghue, K; Drummond, C; Elzerbi, C; Pilling, S; Saunders, R; Whittington, C | 1 |
| Higuchi, S | 1 |
| Saitz, R | 1 |
| Lieb, M; Soyka, M | 1 |
| Carrasco, A; Hu, W; Kroener, S; Morris, B | 1 |
| Frohe, T; Kirouac, M; Maisto, SA; McCallion, E; Vowles, KE; Witkiewitz, K | 1 |
| Chalk, M; Lubran, R; Mark, TL; McCance-Katz, EF; Richardson, J | 1 |
| Brower, KJ | 1 |
| Plosker, GL | 1 |
| Fucito, L; Gueorguieva, R; O'Connor, PG; O'Malley, SS; Tsai, WM; Wu, R; Zhang, H | 1 |
| Bähr, M; Doeppner, TR; Hermann, DM; Kaltwasser, B; Kilic, E; Pehlke, JR; Schlechter, J | 1 |
| Biernacka, JM; Choi, DS; Frye, MA; Geske, JR; Hinton, DJ; Ho, AM; Karpyak, VM; Nam, HW; Prieto, ML; Weinshilboum, RM | 1 |
| Agabio, R; Franconi, F; Gessa, GL; Pani, PP; Preti, A | 1 |
| Gofman, AG; Ponizovskiy, PA | 1 |
| Liang, M; Luo, Z; Mei, Y; Miao, J; Qin, Y; Shen, Y; Wang, Y | 1 |
| Mitani, Y; Nabeshima, T; Nakamura, T; Oki, Y; Shimizu, C | 1 |
| Higuchi, S; Yumoto, Y | 1 |
| Helton, SG; Lohoff, FW | 1 |
| Cholet, N; Chumakov, I; Cohen, D; Foucquier, J; Guedj, M; Hajj, R; Laffaire, J; Milet, A; Mitry, R; Nabirotchkin, S; Robelet, S; Toulorge, D | 1 |
| Anton, RF; Fitzmaurice, GM; Griffin, ML; McHugh, RK; Weiss, RD | 1 |
| Houck, J; Longabaugh, R; Miller, WR; Moyers, TB; Rice, SL | 1 |
| Aguiar, FS; Choi, DS; Hinton, DJ; Ho, AM; Jia, YF; Karpyak, VM; Qiu, Y; Weinshilboum, RM | 1 |
| Creedon, TB; Hodgkin, D; Horgan, CM; Matteucci, AM; Reif, S; Stewart, MT | 1 |
| Cicin-Šain, L; Kovak-Mufić, A; Marušić, S; Matošić, A; Vidrih, B | 1 |
| Baillie, A; Haber, PS; Logge, W; Morley, KC; Pearson, SA | 2 |
| Salisbury-Afshar, E | 1 |
| Bramness, JG; Mann, K; Wurst, FM | 1 |
| Mann, K; Roos, CR; Witkiewitz, K | 1 |
| Dunn, KE; Han, D; Harrison, JA; Leoutsakos, JM; Strain, EC | 1 |
| Bowe, T; Christopher, M; Finlay, AK; Gidwani, R; Hagedorn, H; Harris, AH; Kay, C; Nevedal, A; Rosen, C | 1 |
| Crits-Christoph, P; Gallop, R; Gastfriend, DR; Gibbons, MB; Lundy, C; Markell, HM; Stringer, M | 1 |
| Biernacka, JM; Choi, DS; Feeder, SE; Frye, MA; Gunderson, LJ; Hinton, DJ; Karpyak, VM; Port, JD | 1 |
| Metrik, J; Patterson, D; Subbaraman, MS; Swift, R | 1 |
| Brewer, C; Skinner, M; Streel, E | 1 |
| Goh, ET; Morgan, MY | 1 |
| Manolopoulos, VG; Ragia, G | 1 |
| Ashcroft, DM; Owens, L; Pirmohamed, M; Thompson, A; van Staa, TP | 1 |
| Bowe, TR; Burden, JL; Ellerbe, LS; Finlay, AK; Gupta, S; Harris, AHS; Rubinsky, AD; Timko, C; Wong, JJ | 1 |
| Gomes, T; Martins, D; Singh, S; Spithoff, S; Turner, S | 1 |
| Hallgren, KA; Heather, N; Kirouac, M; Maisto, SA; Montes, KS; Pearson, MR; Roos, CR; Wilson, AD; Witkiewitz, K | 1 |
| Lyon, J | 1 |
| Barkley-Levenson, A; Crabbe, JC; Hack, WR; Huang, LC; Metten, P; Ozburn, AR; Schlumbohm, JP; Spence, SE | 1 |
| Ericson, M; Lidö, HH; Söderpalm, B | 1 |
| Bonnet, U; Dembski, N; Niederhofer, A; Niederhofer, E; Nyhuis, PW; Scherbaum, N; Schifano, F; Specka, M; Tenbergen, M | 1 |
| Bantel, AP; Hutson, RL; Tessier, CR; Thompson, RL | 1 |
| Jin, R; Pan, J; Shen, M; Wu, R; Xu, S | 1 |
| Hughes, JR; Klemperer, EM; Naud, S | 1 |
| Kranzler, HR; Soyka, M | 1 |
| Agabio, R; Balia, S; Gessa, GL; Pani, PP | 1 |
| Pal, H | 1 |
| Biernacka, JM; Choi, DS; Frye, MA; Geske, JR; Ho, MF; Karpyak, VM; Li, H; Moon, I; Oesterle, TS; Seppala, MD; Skime, MK; Wei, L; Weinshilboum, RM; Zhang, C; Zhang, L | 1 |
| Kroener, S; Luo, Y; Manepalli, R; Melugin, PR; Munoz, C; Nofal, A; Phensy, A; Pradhan, G; Wu, F | 1 |
| Ademar, K; Adermark, L; Ericson, M; Söderpalm, B | 1 |
| Gomes, T; Konstantelos, N; Lecce, P; McCormack, D; Tadrous, M; Tourchian, N | 1 |
| Gorczyca, P; Piegza, M; Pudlo, R; Stokłosa, I; Stokłosa, M; Więckiewicz, G | 1 |
148 review(s) available for taurine and acamprosate
| Article | Year |
|---|---|
Acamprosate in alcohol dependence: how does it work?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Clinical Trials as Topic; Combined Modality Therapy; Humans; Motivation; Recurrence; Taurine; Treatment Outcome | 1995 |
Clinical evaluation of acamprosate to reduce alcohol intake.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Controlled Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Taurine | 1993 |
Acamprosate as an aid in the treatment of alcoholism.
Topics: Acamprosate; Alcoholism; gamma-Aminobutyric Acid; Humans; Taurine | 1995 |
The pharmacological treatment of alcohol dependence: needs and possibilities.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Germany; Humans; Patient Care Team; Psychotropic Drugs; Taurine; Treatment Outcome | 1996 |
Subtypes of alcoholism and their role in therapy.
Topics: Acamprosate; Alcoholism; Humans; Taurine; Treatment Outcome | 1996 |
Recent developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Anti-Anxiety Agents; Buspirone; Disulfiram; Ethanol; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; Taurine | 1996 |
Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991.
Topics: Acamprosate; Alcohol Withdrawal Delirium; Alcoholism; Anxiety Disorders; Comorbidity; Depressive Disorder; Humans; Motivation; Narcotic Antagonists; Psychotropic Drugs; Taurine; Treatment Outcome | 1996 |
[Pharmacotherapy of alcoholism].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Dopamine Agents; Humans; Narcotic Antagonists; Psychotropic Drugs; Recurrence; Serotonin Agents; Taurine | 1996 |
Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
Topics: Acamprosate; Alcoholism; Animals; Behavior, Animal; Calcium Channels; Disease Models, Animal; Humans; Naltrexone; Narcotic Antagonists; Neurons; Rats; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Recurrence; Substance Withdrawal Syndrome; Synaptic Transmission; Taurine | 1997 |
The pharmacological treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depression; Disulfiram; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine | 1997 |
Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Tolerance; Ethanol; Humans; Substance Withdrawal Syndrome; Taurine | 1997 |
[Pharmacological treatment of alcohol dependence. Acamprosate and naltrexone offer new approach].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Narcotic Antagonists; Randomized Controlled Trials as Topic; Social Support; Taurine | 1997 |
Acamprosate for alcohol dependence?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Controlled Clinical Trials as Topic; Humans; Substance Withdrawal Syndrome; Taurine; Temperance | 1997 |
[Alcoholism: relapse prevention].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Humans; Medical History Taking; Psychotherapy; Recurrence; Surveys and Questionnaires; Taurine | 1997 |
[New drugs in the treatment of alcoholism].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcoholism; Brain; Humans; Receptors, Neurotransmitter; Taurine; Treatment Outcome | 1997 |
Advances in development of medications for alcoholism treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Drug Therapy, Combination; Humans; Naltrexone; Taurine | 1998 |
Clinical pharmacokinetics of acamprosate.
Topics: Acamprosate; Age Factors; Alcohol Deterrents; Animals; Desipramine; Diazepam; Disulfiram; Dose-Response Relationship, Drug; Drug Interactions; Ethanol; Food-Drug Interactions; Humans; Imipramine; Psychotropic Drugs; Sex Characteristics; Taurine | 1998 |
The pharmacological treatment of alcohol dependence: needs and possibilities.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Humans; Recurrence; Taurine | 1996 |
Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Bupropion; Forecasting; Humans; Methadyl Acetate; Naltrexone; Substance-Related Disorders; Taurine; Tobacco Use Disorder | 1999 |
[Prevention of recurrent alcoholism with acamprosate. Neurobiological principles and clinical results].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Brain; Clinical Trials as Topic; Humans; Receptors, GABA-A; Receptors, N-Methyl-D-Aspartate; Taurine; Treatment Outcome | 1999 |
Pharmacological treatment of alcohol dependence: a review of the evidence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Lithium; Naltrexone; Narcotic Antagonists; Serotonin Agents; Taurine | 1999 |
[Evaluation of drug treatment of primary alcoholism].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Follow-Up Studies; Humans; Naltrexone; Self-Help Groups; Taurine; Treatment Outcome | 1999 |
Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Ethanol; Humans; Neurotransmitter Agents; Taurine | 2000 |
New therapies for alcohol problems: application to primary care.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Primary Health Care; Psychotherapy; Research Design; Taurine; United States | 2000 |
Neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Receptors, N-Methyl-D-Aspartate; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine | 2000 |
Medications to treat alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Calcium Channel Blockers; Dopamine Antagonists; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Taurine | 1999 |
Animal models of craving for ethanol.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Operant; Disease Models, Animal; Drug Tolerance; Motivation; Naltrexone; Narcotic Antagonists; Predictive Value of Tests; Rats; Reinforcement, Psychology; Reproducibility of Results; Substance Withdrawal Syndrome; Taurine | 2000 |
New developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Adjuvants, Anesthesia; Alcohol Deterrents; Alcoholism; Anticonvulsants; Buspirone; Carbamazepine; Drug Therapy; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Ritanserin; Serotonin Agents; Sodium Oxybate; Substance Withdrawal Syndrome; Taurine; Valproic Acid; Vigabatrin | 2001 |
Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Humans; Naltrexone; Narcotic Antagonists; Prosencephalon; Rats; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Serotonin Agents; Taurine | 2001 |
Mechanisms of alcohol-nicotine interactions: alcoholics versus smokers.
Topics: Acamprosate; Acetylcholine; Alcohol Deterrents; Alcoholism; Animals; Central Nervous System Depressants; Drug Interactions; Ethanol; Gene Expression; Humans; Male; Nicotine; Nicotinic Agonists; Rats; Receptors, Nicotinic; Reinforcement, Psychology; Secondary Prevention; Smoking; Taurine; Vasodilator Agents; Ventral Tegmental Area | 2001 |
Naltrexone and acamprosate. Using new drugs for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Australia; Clinical Trials as Topic; Female; Guidelines as Topic; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Satisfaction; Prognosis; Taurine; Treatment Outcome | 2001 |
Pharmacotherapy for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Health Policy; Humans; Lithium; Naltrexone; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Serotonin Agents; Taurine; United States | 1999 |
[Alcohol--mechanism of action, interactions and treatment of alcohol abuse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Interactions; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Taurine | 1998 |
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Taurine; Treatment Outcome | 2001 |
Pharmacologic approaches to the management of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Clinical Trials as Topic; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2001 |
Treatment of alcohol-dependent outpatients with acamprosate: a clinical review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Ambulatory Care; Behavior, Addictive; Controlled Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Humans; International Cooperation; Placebos; Secondary Prevention; Taurine; Treatment Outcome | 2001 |
Acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Interactions; Humans; Substance Withdrawal Syndrome; Taurine | 2002 |
[Long-term treatment of alcohol dependance].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Disulfiram; Family Therapy; Humans; Long-Term Care; Naltrexone; Psychotherapy; Self-Help Groups; Social Support; Social Work; Taurine; Treatment Outcome | 2002 |
New pharmacotherapies for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Self-Help Groups; Taurine; Treatment Outcome | 2002 |
Interactions between taurine and ethanol in the central nervous system.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior; Behavior, Animal; Central Nervous System; Ethanol; gamma-Aminobutyric Acid; Humans; Motor Activity; Taurine | 2002 |
Acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Double-Blind Method; Humans; Multicenter Studies as Topic; Naltrexone; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2003 |
Research advances in the understanding and treatment of addiction.
Topics: Acamprosate; Alcohol Deterrents; Brain; Chronic Disease; Disease Progression; Humans; Naltrexone; Narcotics; Prognosis; Recurrence; Risk Factors; Substance-Related Disorders; Taurine | 2003 |
Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Double-Blind Method; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine | 2003 |
Pharmacology of acamprosate: an overview.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Biological Availability; Humans; Intestinal Absorption; Receptors, N-Methyl-D-Aspartate; Taurine | 2003 |
The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis.
Topics: Acamprosate; Alcoholism; Confidence Intervals; Humans; Randomized Controlled Trials as Topic; Taurine; Temperance | 2004 |
[Neural basis of alcohol dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Dopamine; Ethanol; Humans; Narcotic Antagonists; Neurons; Nucleus Accumbens; Secondary Prevention; Taurine | 2003 |
[Drug therapy of alcohol dependence--a critical review].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Fructose; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Topiramate | 2003 |
Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Brain; Humans; Naltrexone; Narcotic Antagonists; Receptors, Glutamate; Recurrence; Taurine | 2003 |
Current pharmacotherapies of alcoholism: a U.S. perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Receptors, Glutamate; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine; United States | 2003 |
Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Europe; Humans; Meta-Analysis as Topic; Naltrexone; Narcotic Antagonists; Placebos; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Taurine; Treatment Outcome | 2003 |
Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2004 |
Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients.
Topics: Acamprosate; Adult; Age Factors; Aged; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anxiety; Double-Blind Method; Ethanol; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Motivation; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Sex Factors; Substance Withdrawal Syndrome; Taurine; Treatment Outcome | 2005 |
Recent advances in the pharmacotherapy of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Clinical Trials as Topic; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neurotransmitter Agents; Taurine; Topiramate | 2004 |
[Advances in the treatment of alcohol dependence: pharmacological relapse prevention].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Ethanol; Humans; Randomized Controlled Trials as Topic; Secondary Prevention; Substance Withdrawal Syndrome; Taurine; Treatment Outcome | 2003 |
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Clinical Trials as Topic; Disulfiram; Excitatory Amino Acid Antagonists; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2004 |
Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Humans; Taurine | 2005 |
Acamprosate (Campral) for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Costs; Drug Interactions; Humans; Randomized Controlled Trials as Topic; Taurine | 2005 |
Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action.
Topics: Acamprosate; Alcoholism; Animals; Drug Interactions; Ethanol; Excitatory Amino Acids; Humans; Models, Biological; Neuroprotective Agents; Receptors, Glutamate; Taurine | 2005 |
Acamprosate for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Diarrhea; Humans; Meta-Analysis as Topic; Molecular Structure; Randomized Controlled Trials as Topic; Taurine | 2005 |
Acamprosate in the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Taurine; Treatment Outcome | 2005 |
Combining treatments for alcoholism: why and how?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Taurine | 2005 |
COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.
Topics: Acamprosate; Alcohol Dehydrogenase; Alcohol Deterrents; Alcoholism; Alleles; Combined Modality Therapy; Drug Therapy; Genetic Markers; Genotype; Haplotypes; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Psychotherapy; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Taurine | 2005 |
Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2005 |
Pharmacotherapy of alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amitriptyline; Antidepressive Agents, Tricyclic; Comorbidity; Disulfiram; Dopamine; Drug Interactions; Ethanol; Female; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Male; Mental Disorders; Naltrexone; Narcotics; Serotonin; Taurine | 2005 |
Medications for treating alcohol dependence.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Disulfiram; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Randomized Controlled Trials as Topic; Serotonin Agents; Taurine; Treatment Outcome | 2005 |
Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Naltrexone; Rodentia; Taurine | 2005 |
Alcoholism and suicidal behavior: a clinical overview.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents, Tricyclic; Anxiety; Comorbidity; Depressive Disorder, Major; Humans; Hydroxyindoleacetic Acid; Naltrexone; Narcotic Antagonists; Personality Disorders; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Suicide; Suicide, Attempted; Taurine | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Neuropeptide Y; Nociceptin; Ondansetron; Opioid Peptides; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Taurine; Topiramate | 2006 |
Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; gamma-Aminobutyric Acid; Glutamine; Humans; Models, Biological; Models, Neurological; N-Methylaspartate; Naltrexone; Narcotic Antagonists; Neurons; Polymorphism, Genetic; Receptors, Opioid, mu; Recurrence; Taurine | 2006 |
What's new in clinical pharmacology and therapeutics.
Topics: Acamprosate; Amyloid; Azabicyclo Compounds; Daptomycin; Diphosphonates; Drug Approval; Humans; Ibandronic Acid; Influenza Vaccines; Islet Amyloid Polypeptide; Ketolides; Lanthanum; Memantine; Pharmacology, Clinical; Piperazines; Rifamycins; Rifaximin; Scopolamine Derivatives; Taurine; Tiotropium Bromide; United States; United States Food and Drug Administration | 2006 |
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Alzheimer Disease; Brain; Dopamine Agents; Humans; Memantine; Mental Disorders; Psychotropic Drugs; Taurine | 2006 |
Choosing the right medication for the treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Choice Behavior; Cognitive Behavioral Therapy; Combined Modality Therapy; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Taurine; Topiramate | 2006 |
[Neurobiological mechanisms and pharmacological treatment options for alcohol craving].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Neurotransmitter Agents; Receptors, Glutamate; Taurine | 2007 |
New pharmacological approaches for the treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Carbamazepine; Depression; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Secondary Prevention; Taurine; Topiramate | 2006 |
Trends in the adoption of medications for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Longitudinal Studies; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Taurine; United States | 2006 |
[Pharmacological relapse prevention in alcohol and tobacco dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; Humans; Naltrexone; Nicotine; Psychotherapy; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Taurine; Tobacco Use Disorder | 2007 |
Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Animals; Antipsychotic Agents; Clozapine; Diagnostic Imaging; Glutamates; Humans; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Substance-Related Disorders; Taurine | 2006 |
Preclinical and clinical pharmacology of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disulfiram; Dopamine; GABA Modulators; Glutamic Acid; Humans; Naltrexone; Narcotic Antagonists; Serotonin; Taurine | 2007 |
Glutamate-modulating drugs & the treatment of mental disorders.
Topics: Acamprosate; Amantadine; Cycloserine; Glutamic Acid; Humans; Ketamine; Lamotrigine; Memantine; Mental Disorders; Psychotropic Drugs; Riluzole; Taurine; Triazines | 2007 |
Emerging approaches to managing alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Brain; Disulfiram; Drug Therapy, Combination; Ethanol; Humans; Naltrexone; Taurine | 2007 |
Improving adherence in patients with alcohol dependence: a new role for pharmacists.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Disulfiram; Humans; Naltrexone; Patient Compliance; Pharmacists; Professional Role; Taurine; Treatment Refusal | 2007 |
Therapeutics for alcoholism: what's the future?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Brain; Cannabinoid Receptor Antagonists; Humans; Mice; Peptides, Cyclic; Rats; Receptor, Metabotropic Glutamate 5; Receptors, Corticotropin-Releasing Hormone; Receptors, GABA-B; Receptors, Metabotropic Glutamate; Taurine | 2007 |
Substance abuse and schizophrenia: pharmacotherapeutic intervention.
Topics: Acamprosate; Alcohol Deterrents; Antipsychotic Agents; Clozapine; Disulfiram; Drug Interactions; Humans; Naltrexone; Narcotics; Schizophrenia; Substance-Related Disorders; Taurine | 2008 |
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Receptors, N-Methyl-D-Aspartate; Ritanserin; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate | 2008 |
Treatment of tinnitus with acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Excitatory Amino Acid Antagonists; GABA Agents; Humans; Taurine; Tinnitus | 2007 |
Acamprosate in the treatment of alcohol dependence: clinical and economic considerations.
Topics: Acamprosate; Alcoholism; Humans; Randomized Controlled Trials as Topic; Taurine | 2007 |
Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Publication Bias; Secondary Prevention; Taurine | 2008 |
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biological Psychiatry; Carbamazepine; Disulfiram; Fructose; Health Planning Guidelines; Humans; Naltrexone; Ondansetron; Societies, Scientific; Substance-Related Disorders; Taurine; Topiramate | 2008 |
[Alcohol dependence: diagnosis and treatment].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Disulfiram; Humans; Motivation; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Taurine | 2008 |
Acamprosate: recent findings and future research directions.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; gamma-Aminobutyric Acid; Glutamates; Humans; Neuroprotective Agents; Patient Selection; Secondary Prevention; Taurine | 2008 |
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Single-Blind Method; Taurine | 2008 |
Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.
Topics: Acamprosate; Age of Onset; Antipsychotic Agents; Glutamic Acid; Humans; Neurosciences; Psychopharmacology; Schizophrenia; Schizophrenic Psychology; Synaptic Transmission; Taurine | 2008 |
The state of pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations; Disulfiram; Fructose; Humans; Medication Adherence; Naltrexone; Taurine; Temperance; Topiramate | 2009 |
[Recent results in relaps prevention of alcoholism with Disulfiram].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Aldehyde Dehydrogenase; Combined Modality Therapy; Disulfiram; Drug Interactions; Drug Therapy, Combination; Germany; Humans; Metabolic Clearance Rate; Motivation; Naltrexone; Randomized Controlled Trials as Topic; Secondary Prevention; Taurine | 2008 |
The implications of medication development in the treatment of substance use disorders in developing countries.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Comorbidity; Developing Countries; Disulfiram; HIV Infections; Humans; Methadone; Narcotic Antagonists; Prevalence; Public Policy; Substance Abuse, Intravenous; Substance-Related Disorders; Taurine | 2009 |
Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Delayed-Action Preparations; Dopamine; Drug Therapy, Combination; Humans; Motivation; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Receptors, Opioid; Secondary Prevention; Taurine; Temperance; Ventral Tegmental Area | 2008 |
The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Cognition; Diarrhea; Disease Models, Animal; Drug Interactions; Humans; Randomized Controlled Trials as Topic; Receptors, Glutamate; Sleep Initiation and Maintenance Disorders; Synaptic Transmission; Taurine; Treatment Outcome | 2010 |
Acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Randomized Controlled Trials as Topic; Taurine | 2010 |
Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Brain; Brain Chemistry; Humans; Neurotransmitter Agents; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Taurine; Treatment Outcome | 2010 |
Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Drug Delivery Systems; Humans; Molecular Biology; Pharmacogenetics; Precision Medicine; Taurine | 2010 |
Effect of early and late compliance on the effectiveness of acamprosate in the treatment of alcohol dependence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Medication Adherence; Middle Aged; Motivation; Randomized Controlled Trials as Topic; Regression Analysis; Secondary Prevention; Taurine; Temperance; Time Factors | 2010 |
Acamprosate for alcohol dependence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Diarrhea; Humans; Placebo Effect; Randomized Controlled Trials as Topic; Taurine | 2010 |
Addiction treatment: level of care determination.
Topics: Acamprosate; Alcohol Deterrents; Behavior Therapy; Cognitive Behavioral Therapy; Health Status Indicators; Humans; Inpatients; Mass Screening; Naltrexone; Narcotic Antagonists; Outpatients; Primary Health Care; Substance-Related Disorders; Taurine | 2011 |
How cognitive assessment through clinical neurophysiology may help optimize chronic alcoholism treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognition; Humans; Naltrexone; Psychotherapy; Taurine | 2011 |
Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Randomized Controlled Trials as Topic; Sex Characteristics; Taurine | 2012 |
A literature review of cost-benefit analyses for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Belgium; Cost-Benefit Analysis; Humans; Psychotherapy; Spain; Taurine; Time Factors; Treatment Outcome; United States | 2011 |
Strategies for evaluating the economic value of drugs in alcohol dependence treatment.
Topics: Acamprosate; Alcoholism; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Naltrexone; Taurine; Treatment Outcome | 2012 |
Opioid antagonists for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Motivation; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Secondary Prevention; Taurine; Treatment Outcome | 2011 |
[Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram--a systematic review].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Evidence-Based Medicine; Humans; Naltrexone; Taurine; Treatment Outcome | 2011 |
New pharmacological treatment strategies for relapse prevention.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Animals; Disulfiram; Drugs, Investigational; History, 18th Century; History, 21st Century; Humans; Naltrexone; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Taurine | 2013 |
Medical treatment of alcohol dependence: a systematic review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Antagonists; Off-Label Use; Taurine; Topiramate; Treatment Outcome | 2011 |
[Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Female; Humans; Middle Aged; Naltrexone; Secondary Prevention; Taurine; Treatment Outcome | 2013 |
Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Ethanol; Humans; Inactivation, Metabolic; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Time Factors; Treatment Outcome | 2013 |
[The patient with an alcohol abuse problem family doctor practice].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Family Practice; Humans; Poland; Practice Patterns, Physicians'; Taurine | 2012 |
The clinical pharmacology of acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Humans; Rodentia; Secondary Prevention; Substance Withdrawal Syndrome; Taurine | 2014 |
The current situation of treatment systems for alcoholism in Korea.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Benzodiazepines; Humans; Naltrexone; Psychotherapy; Republic of Korea; Taurine | 2013 |
Medications for unhealthy alcohol use: across the spectrum.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Disulfiram; Dopamine Agents; Fructose; Humans; Naltrexone; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate | 2011 |
Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain Chemistry; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2008 |
Pharmacotherapy for alcohol dependence: status of current treatments.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Disulfiram; Humans; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Taurine | 2013 |
Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Biomedical Research; Drug Industry; Health Services Needs and Demand; Humans; Insurance, Health, Reimbursement; Naltrexone; Narcotic Antagonists; Taurine | 2014 |
The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebo Effect; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2013 |
[New treatment options for alcohol dependence].
Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; Psychotherapy; Secondary Prevention; Socioenvironmental Therapy; Substance Withdrawal Syndrome; Taurine; Topiramate | 2013 |
Pharmacotherapy of alcohol use disorders: seventy-five years of progress.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Fructose; Humans; Hypnotics and Sedatives; Narcotic Antagonists; Pharmacogenetics; Taurine; Topiramate | 2014 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; Randomized Controlled Trials as Topic; Taurine; Topiramate | 2014 |
A Bayesian mixed-treatment comparison meta-analysis of treatments for alcohol dependence and implications for planning future trials.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bayes Theorem; Humans; Naltrexone; Randomized Controlled Trials as Topic; Review Literature as Topic; Taurine | 2014 |
Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Benzodiazepines; Disulfiram; Ethanol; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Plant Preparations; Receptors, GABA-A; Taurine; Topiramate | 2014 |
The development of acamprosate as a treatment against alcohol relapse.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Humans; Recurrence; Taurine | 2014 |
Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders.
Topics: Acamprosate; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Directive Counseling; Disulfiram; Humans; Methadone; Naltrexone; Narcotic Antagonists; Practice Patterns, Physicians'; Substance-Related Disorders; Taurine; United States | 2014 |
Pharmacologic treatment of alcoholism.
Topics: Acamprosate; Alcoholism; Animals; Brain; Humans; Naltrexone; Nerve Net; Neuroimaging; Pharmacogenetics; Taurine; Valproic Acid | 2014 |
Treatment of alcohol dependence: recent progress and reduction of consumption.
Topics: Acamprosate; Age of Onset; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Binge Drinking; Contraindications; Craving; Disulfiram; Drugs, Investigational; Europe; Humans; Meta-Analysis as Topic; Multicenter Studies as Topic; Naltrexone; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Sodium Oxybate; Taurine | 2014 |
Treatment of the psychiatric problems associated with fragile X syndrome.
Topics: Acamprosate; Adult; Animals; Child; Female; Fragile X Syndrome; Humans; Lovastatin; Male; Mice; Minocycline; Sertraline; Taurine | 2015 |
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Europe; Female; Global Health; Humans; Male; Middle Aged; Naltrexone; Randomized Controlled Trials as Topic; Recurrence; Taurine; Treatment Outcome | 2015 |
Recent Developments in Pharmacotherapy of Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Randomized Controlled Trials as Topic; Taurine; Varenicline | 2015 |
Assessment and treatment of insomnia in adult patients with alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amines; Anti-Anxiety Agents; Anticonvulsants; Antipsychotic Agents; Cognitive Behavioral Therapy; Comorbidity; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Dyssomnias; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Polysomnography; Quetiapine Fumarate; Sleep Apnea Syndromes; Sleep Initiation and Maintenance Disorders; Stress, Psychological; Taurine; Topiramate; Trazodone | 2015 |
Acamprosate: A Review of Its Use in Alcohol Dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Interactions; Humans; Randomized Controlled Trials as Topic; Taurine | 2015 |
Efficacy of Medications Approved for the Treatment of Alcohol Dependence and Alcohol Withdrawal Syndrome in Female Patients: A Descriptive Review.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Benzodiazepines; Disulfiram; Female; Humans; Male; Naltrexone; Sex Factors; Taurine; Treatment Outcome | 2016 |
[Depression in alcohol addicted patients].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depressive Disorder; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Taurine | 2015 |
[Pharmacological therapies for alcohol use disorder in Japan].
Topics: Acamprosate; Alcohol-Related Disorders; Alcohols; Humans; Japan; Naltrexone; Substance Withdrawal Syndrome; Taurine | 2015 |
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Disulfiram; Fructose; Humans; Naltrexone; Pharmacogenetics; Precision Medicine; Taurine; Topiramate; United States | 2015 |
NEUROBIOLOGICAL BASES OF ALCOHOL ADDICTION.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain; Disulfiram; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Minisatellite Repeats; Monoamine Oxidase; Naltrexone; Narcotic Antagonists; Neuropeptide Y; Norepinephrine; Ondansetron; Polymorphism, Genetic; Serotonin; Synaptic Transmission; Taurine | 2016 |
Supervised Disulfiram's Superior Effectiveness in Alcoholism Treatment: Ethical, Methodological, and Psychological Aspects.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bioethical Issues; Disulfiram; Humans; Naltrexone; Taurine | 2017 |
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Humans; Naltrexone; Polymorphism, Single Nucleotide; Pyridoxine; Pyrrolidonecarboxylic Acid; Taurine; Topiramate; Treatment Outcome | 2017 |
Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Pharmacogenetics; Polymorphism, Genetic; Precision Medicine; Taurine | 2017 |
The Glycine Receptor-A Functionally Important Primary Brain Target of Ethanol.
Topics: Acamprosate; Alcohol Drinking; Animals; Brain; Dopamine; Ethanol; Humans; Naltrexone; Receptors, Glycine; Taurine | 2017 |
Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Randomized Controlled Trials as Topic; Substance-Related Disorders; Taurine; Treatment Outcome | 2018 |
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Counseling; Disulfiram; Humans; Naltrexone; Taurine | 2018 |
[Pharmacotherapy of alcohol withdrawal: update and new developments].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Germany; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2021 |
Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Pharmaceutical Preparations; Public Health; Taurine | 2023 |
103 trial(s) available for taurine and acamprosate
| Article | Year |
|---|---|
[Effect of acute administration of acamprosate on the risk of encephalopathy and on arterial pressure in patients with alcoholic cirrhosis].
Topics: Acamprosate; Administration, Oral; Adult; Blood Pressure; Double-Blind Method; Drug Evaluation; Evoked Potentials, Visual; Female; Hepatic Encephalopathy; Humans; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Placebos; Reference Values; Risk Factors; Taurine | 1992 |
Acamprosate appears to decrease alcohol intake in weaned alcoholics.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Liver Function Tests; Male; Middle Aged; Taurine | 1990 |
Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics.
Topics: Acamprosate; Adult; Alcoholism; Clinical Trials as Topic; Double-Blind Method; Erythrocyte Indices; Female; gamma-Glutamyltransferase; Humans; Male; Middle Aged; Receptors, GABA-A; Recurrence; Substance Withdrawal Syndrome; Taurine | 1985 |
Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcoholism; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Function Tests; Male; Middle Aged; Prospective Studies; Psychotherapy; Single-Blind Method; Taurine; Temperance | 1995 |
[Acamprosate--a stabilizing factor in long-term withdrawal of alcoholic patients].
Topics: Acamprosate; Adult; Alcoholism; Double-Blind Method; Female; Humans; Long-Term Care; Male; Middle Aged; Taurine | 1993 |
Comparison of acamprosate and placebo in long-term treatment of alcohol dependence.
Topics: Acamprosate; Adult; Alcoholism; Double-Blind Method; Ethanol; Female; Follow-Up Studies; Humans; Male; Recurrence; Taurine; Temperance; Time Factors; Treatment Outcome | 1996 |
Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence.
Topics: Acamprosate; Adult; Aged; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Dropouts; Placebos; Recurrence; Survival Analysis; Taurine; Temperance; Treatment Outcome | 1996 |
Subtypes of alcoholism and their role in therapy.
Topics: Acamprosate; Alcoholism; Humans; Taurine; Treatment Outcome | 1996 |
Acamprosate: a new pharmacotherapeutic approach to relapse prevention in alcoholism--preliminary data.
Topics: Acamprosate; Adult; Aged; Alcoholism; Double-Blind Method; Drug Tolerance; Female; gamma-Glutamyltransferase; Humans; Male; Middle Aged; Taurine; Temperance | 1994 |
Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Libido; Male; Middle Aged; Recurrence; Taurine; Temperance; Treatment Outcome | 1997 |
Acamprosate treatment in a long-term community-based alcohol rehabilitation programme.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Community Mental Health Services; Double-Blind Method; Female; Humans; Long-Term Care; Male; Middle Aged; Taurine; Treatment Outcome | 1997 |
Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Disulfiram; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Long-Term Care; Male; Middle Aged; Taurine; Temperance; Treatment Outcome | 1998 |
Lack of psychotomimetic or impairing effects on psychomotor performance of acamprosate.
Topics: Acamprosate; Adult; Affect; Alcohol Deterrents; Attention; Cross-Over Studies; Double-Blind Method; Humans; Illusions; Intelligence Tests; Male; Psychomotor Performance; Psychoses, Substance-Induced; Taurine; Vision, Binocular | 1998 |
Central effects of acamprosate: part 2. Acamprosate modifies the brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers.
Topics: Acamprosate; Adult; Alcohol Deterrents; Aspartic Acid; Brain; Creatine; Cross-Over Studies; Dipeptides; Double-Blind Method; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Magnetic Resonance Spectroscopy; Male; Phosphocreatine; Taurine | 1998 |
Effects of acamprosate on psychomotor performance and driving ability in abstinent alcoholics.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Automobile Driving; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Psychomotor Performance; Stress, Psychological; Taurine; Temperance; Vision, Ocular | 1998 |
Effects of acamprosate on memory in healthy young subjects.
Topics: Acamprosate; Adult; Alcohol Deterrents; Cognition Disorders; Cross-Over Studies; Humans; Male; Memory; Memory Disorders; Taurine | 1999 |
Lack of effects of acamprosate on anterior pituitary hormone secretion in healthy subjects.
Topics: Acamprosate; Adult; Alcohol Deterrents; Human Growth Hormone; Humans; Hydrocortisone; Infusions, Intravenous; Male; Pituitary Gland, Anterior; Pituitary Hormones, Anterior; Prolactin; Reference Values; Taurine | 1999 |
Economic evaluation of Campral (Acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Belgium; Humans; Markov Chains; Models, Economic; Placebos; Randomized Controlled Trials as Topic; Taurine; Temperance | 2000 |
Acamprosate reduces motor cortex excitability determined by transcranial magnetic stimulation.
Topics: Acamprosate; Adult; Alcohol Deterrents; Anticonvulsants; Cross-Over Studies; Electromagnetic Fields; Evoked Potentials; Humans; Lamotrigine; Male; Motor Cortex; Receptors, GABA; Taurine; Triazines | 2000 |
[Adjuvant drug treatment of alcoholism with acamprosate: between sectoral budgets and disease management].
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Budgets; Cohort Studies; Cost-Benefit Analysis; Female; Germany; Humans; Male; Middle Aged; Taurine; Temperance | 2001 |
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Taurine; Treatment Outcome | 2001 |
Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; GABA Antagonists; Humans; Male; Middle Aged; Patient Compliance; Prospective Studies; Psychiatric Status Rating Scales; Secondary Prevention; Social Support; Substance Withdrawal Syndrome; Survival Analysis; Taurine; Treatment Outcome | 2002 |
[Acamprosate and psychosocial intervention. An integrative treatment approach for prevention of alcohol dependent patients in Switzerland].
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Psychotherapy; Quality of Life; Recurrence; Switzerland; Taurine; Temperance | 2002 |
A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.
Topics: Acamprosate; Adolescent; Adult; Alcohol Deterrents; Alcoholism; Brain; Cognition; Double-Blind Method; Drug Interactions; Drug Tolerance; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Neuropsychological Tests; Reaction Time; Taurine | 2002 |
Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.
Topics: Acamprosate; Alcoholism; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Placebos; Secondary Prevention; Taurine; Treatment Outcome | 2003 |
Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Cohort Studies; Combined Modality Therapy; Cost-Benefit Analysis; Female; Germany; Humans; Male; Middle Aged; National Health Programs; Prospective Studies; Psychotherapy; Secondary Prevention; Social Support; Taurine; Temperance | 2003 |
Acamprosate and its efficacy in treating alcohol dependent adolescents.
Topics: Acamprosate; Adolescent; Adolescent Behavior; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; Humans; Male; Severity of Illness Index; Taurine | 2003 |
Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects.
Topics: Acamprosate; Adult; Alcoholism; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Neuropsychological Tests; Taurine | 2003 |
Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods.
Topics: Acamprosate; Alcoholism; Analysis of Variance; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Taurine | 2003 |
Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study.
Topics: Acamprosate; Adult; Alcoholism; Behavior Therapy; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Male; Middle Aged; Naltrexone; Pilot Projects; Taurine | 2003 |
Efficacy of acamprosate in the treatment of alcohol-dependent outpatients.
Topics: Acamprosate; Adolescent; Adult; Alcohol Deterrents; Alcoholism; Ambulatory Care; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Taurine | 2003 |
Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting.
Topics: Acamprosate; Adolescent; Adult; Alcoholism; Ambulatory Care; Analysis of Variance; Chi-Square Distribution; Follow-Up Studies; Humans; Male; Middle Aged; Statistics, Nonparametric; Survival Analysis; Taurine | 2004 |
Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Arousal; Cerebral Cortex; Double-Blind Method; Electroencephalography; Humans; Male; Middle Aged; Placebos; Substance Withdrawal Syndrome; Taurine | 2004 |
Hypothalamic-pituitary-adrenal system regulation in recently detoxified alcoholics is not altered by one week of treatment with acamprosate.
Topics: Acamprosate; Administration, Oral; Adrenocorticotropic Hormone; Adult; Alcohol Deterrents; Alcoholism; Case-Control Studies; Corticotropin-Releasing Hormone; Female; Follow-Up Studies; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Multivariate Analysis; Pituitary-Adrenal System; Taurine; Treatment Outcome | 2004 |
Alcohol effects during acamprosate treatment: a dose-response study in humans.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholic Intoxication; Analysis of Variance; Dose-Response Relationship, Drug; Double-Blind Method; Ethanol; Female; Humans; Male; Middle Aged; Psychomotor Performance; Taurine | 2004 |
Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Anxiety Disorders; Depression; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotics; Predictive Value of Tests; Prospective Studies; Secondary Prevention; Somatoform Disorders; Surveys and Questionnaires; Taurine; Treatment Outcome | 2005 |
Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; Humans; Leptin; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Recurrence; Taurine | 2005 |
The efficacy of compliance therapy in pharmacotherapy for alcohol dependence: a randomized controlled trial.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Middle Aged; Patient Compliance; Surveys and Questionnaires; Taurine; Treatment Outcome | 2005 |
Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?
Topics: Acamprosate; Adrenocorticotropic Hormone; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Taurine; Time Factors | 2006 |
Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; Humans; Male; Motivation; Placebos; Taurine; Treatment Outcome | 2006 |
A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Anticonvulsants; Carbamazepine; Female; Humans; Male; Middle Aged; Oxcarbazepine; Pilot Projects; Recurrence; Taurine | 2006 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebo Effect; Taurine | 2006 |
Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Central Nervous System Depressants; Compulsive Personality Disorder; Double-Blind Method; Electrophysiology; Ethanol; Humans; Male; Polysomnography; Psychiatric Status Rating Scales; Sleep; Sleep, REM; Substance Withdrawal Syndrome; Taurine | 2006 |
Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety; Australia; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Placebos; Secondary Prevention; Taurine; Treatment Outcome | 2006 |
Psychometrics of the Drinker Inventory of Consequences (DrInC).
Topics: Acamprosate; Alcoholism; Combined Modality Therapy; Factor Analysis, Statistical; Follow-Up Studies; Humans; Naltrexone; Narcotic Antagonists; Psychometrics; Psychotherapy; Surveys and Questionnaires; Taurine | 2007 |
Measuring economic outcomes of alcohol treatment using the Economic Form 90.
Topics: Absenteeism; Acamprosate; Accidents, Traffic; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Criminal Law; Employment; Female; Follow-Up Studies; Health Care Costs; Health Resources; Humans; Male; Middle Aged; Models, Economic; Naltrexone; Prisons; Taurine; Treatment Outcome; United States | 2007 |
The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.
Topics: Acamprosate; Affect; Alcohol Deterrents; Alcoholism; Autonomic Nervous System; Cues; Double-Blind Method; Galvanic Skin Response; Heart Rate; Humans; Hydrocortisone; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Patient Compliance; Psychiatric Status Rating Scales; Surveys and Questionnaires; Taurine | 2007 |
Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Middle Aged; Taurine; Treatment Outcome | 2008 |
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Topics: Acamprosate; Adult; Alcoholism; Alleles; Amino Acid Substitution; Asparagine; Aspartic Acid; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Genetic Carrier Screening; Genetic Markers; Genotype; Homozygote; Humans; Liver Function Tests; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Genetic; Prognosis; Receptors, Opioid, mu; Taurine; Temperance; Treatment Outcome | 2008 |
Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Taurine; Treatment Outcome | 2008 |
Relationship between medication adherence and treatment outcomes: the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Taurine; Temperance; Treatment Outcome; United States | 2008 |
Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Taurine; Temperance | 2008 |
Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Negativism; Placebo Effect; Secondary Prevention; Taurine; Temperance; Treatment Outcome | 2008 |
Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Dopamine Agents; Double-Blind Method; Excitatory Amino Acid Agents; Female; Germany; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Psychotherapy; Reflex; Taurine; United States; Young Adult | 2009 |
The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Analysis of Variance; Behavior, Addictive; Body Temperature; Cues; Double-Blind Method; Ethanol; Female; Galvanic Skin Response; Humans; Hydrocortisone; Male; Middle Aged; Pain Measurement; Patient Compliance; Psychiatric Status Rating Scales; Statistics as Topic; Taurine; Time Factors | 2009 |
Blood glucose level, alcohol heavy drinking, and alcohol craving during treatment for alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Blood Glucose; Counseling; Female; Humans; Male; Middle Aged; Naltrexone; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Taurine | 2009 |
Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Cues; Female; Genotype; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Genetic; Receptors, Dopamine D2; Receptors, GABA-A; Receptors, Opioid, mu; Taurine; Treatment Outcome | 2009 |
Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Black or African American; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2009 |
The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin.
Topics: Acamprosate; Adrenocorticotropic Hormone; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; beta-Endorphin; Double-Blind Method; Female; Hormones; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Pituitary-Adrenal System; Taurine; Time Factors; Treatment Outcome | 2009 |
Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels.
Topics: Acamprosate; Administration, Oral; Alcohol Deterrents; Calibration; China; Chromatography, High Pressure Liquid; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Spectrometry, Mass, Electrospray Ionization; Taurine; Young Adult | 2009 |
[Impact of functional social support for abstinence after inpatient detoxification].
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Prognosis; Prospective Studies; Psychotherapy, Group; Retreatment; Secondary Prevention; Social Support; Surveys and Questionnaires; Taurine | 2010 |
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Corticotropin-Releasing Hormone; Creatine; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucocorticoids; Glutamic Acid; Gyrus Cinguli; Humans; Magnetic Resonance Spectroscopy; Male; Taurine | 2010 |
Network support as a prognostic indicator of drinking outcomes: the COMBINE Study.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Prognosis; Social Support; Taurine; Temperance; Treatment Outcome | 2010 |
Acamprosate calcium as augmentation therapy for anxiety disorders.
Topics: Acamprosate; Adult; Anti-Anxiety Agents; Anxiety Disorders; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Taurine | 2010 |
Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial.
Topics: Acamprosate; Adult; Binge-Eating Disorder; Body Mass Index; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Taurine; Treatment Outcome; Weight Gain | 2011 |
A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence.
Topics: Acamprosate; Alcohol Deterrents; Central Nervous System Agents; Cocaine; Cocaine-Related Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Philadelphia; Pilot Projects; Taurine; Treatment Outcome | 2011 |
Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Family; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Placebos; Sex Characteristics; Substance-Related Disorders; Taurine; Treatment Outcome | 2011 |
Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Taurine; Temperance | 2011 |
Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
Topics: Acamprosate; Adult; Affect; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2011 |
Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate.
Topics: Acamprosate; Adrenergic alpha-2 Receptor Antagonists; Adult; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Anxiety; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Placebos; Serotonin Receptor Agonists; Severity of Illness Index; Taurine; Treatment Failure; Yohimbine | 2011 |
Marked reduction of heavy drinking did not reduce nicotine use over 1 year in a clinical sample of alcohol-dependent patients.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Ethanol; Female; Humans; Male; Nicotinic Agonists; Smoking; Taurine; Temperance; Tobacco Use Disorder | 2011 |
Self-efficacy change as a mediator of associations between therapeutic bond and one-year outcomes in treatments for alcohol dependence.
Topics: Acamprosate; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Professional-Patient Relations; Self Efficacy; Taurine; Treatment Outcome | 2011 |
The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Counseling; Female; Humans; Male; Middle Aged; Outpatients; Recurrence; Taurine; Treatment Outcome | 2011 |
Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Anxiety Disorders; Bipolar Disorder; Comorbidity; Female; Humans; Male; Middle Aged; Patient Compliance; Predictive Value of Tests; Taurine; Treatment Outcome | 2011 |
Effects of acamprosate on cognition in a treatment study of patients with schizophrenia spectrum disorders and comorbid alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognition; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Taurine | 2011 |
Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Random Allocation; Taurine; Temperance; Treatment Outcome | 2012 |
Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior, Addictive; Bipolar Disorder; Depression; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Markov Chains; Middle Aged; Psychiatric Status Rating Scales; Taurine | 2012 |
An open-label trial of acamprosate in the treatment of pathological gambling.
Topics: Acamprosate; Female; Gambling; Humans; Interview, Psychological; Male; Middle Aged; Psychiatric Status Rating Scales; Psychotropic Drugs; Taurine; Treatment Outcome | 2011 |
An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.
Topics: Acamprosate; Autistic Disorder; Child; Excitatory Amino Acid Antagonists; GABA Antagonists; Humans; Pilot Projects; Psychiatric Status Rating Scales; Social Behavior Disorders; Taurine | 2011 |
Does session attendance by a supportive significant other predict outcomes in individual treatment for alcohol use disorders?
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Forecasting; Humans; Male; Middle Aged; Naltrexone; Social Support; Spouses; Taurine; Treatment Outcome | 2012 |
A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report.
Topics: Acamprosate; Adult; Affect; Alcohol Deterrents; Alcoholism; Bipolar Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Taurine | 2012 |
The cost-effectiveness of tailored, postal feedback on general practitioners' prescribing of pharmacotherapies for alcohol dependence.
Topics: Acamprosate; Adolescent; Adult; Alcoholism; Cost-Benefit Analysis; Female; General Practitioners; Humans; Male; Naltrexone; New South Wales; Postal Service; Practice Patterns, Physicians'; Taurine | 2012 |
Trajectory analyses in alcohol treatment research.
Topics: Acamprosate; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Algorithms; Behavior Therapy; Combined Modality Therapy; Data Interpretation, Statistical; Double-Blind Method; Female; Fructose; Humans; Linear Models; Male; Middle Aged; Models, Statistical; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Nonlinear Dynamics; Regression Analysis; Research; Research Design; Taurine; Topiramate; Treatment Outcome; Young Adult | 2012 |
Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Smoking; Taurine; Treatment Outcome | 2012 |
Simultaneous modeling of the impact of treatments on alcohol consumption and quality of life in the COMBINE study: a coupled hidden Markov analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drug Therapy, Combination; Humans; Markov Chains; Naltrexone; Quality of Life; Taurine; Treatment Outcome | 2012 |
The impact of acamprosate on cue reactivity in alcohol dependent individuals: a functional magnetic resonance imaging study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Brain; Cues; Female; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Single-Blind Method; Taurine | 2012 |
A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder.
Topics: Acamprosate; Adult; Alcoholism; Citalopram; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pilot Projects; Taurine; Treatment Outcome | 2012 |
Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Family Practice; Female; Follow-Up Studies; Humans; Male; Middle Aged; North Carolina; Taurine; Treatment Outcome; United States; Wisconsin | 2013 |
Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Ambulatory Care; Counseling; Disease-Free Survival; Double-Blind Method; Female; Germany; Hospitalization; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Placebos; Randomized Controlled Trials as Topic; Research Design; Taurine; Treatment Outcome; United States | 2013 |
The effects of drinking goal on treatment outcome for alcoholism.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Female; Goals; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Recurrence; Taurine; Treatment Outcome | 2013 |
Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.
Topics: Acamprosate; Adolescent; Biomarkers; Brain-Derived Neurotrophic Factor; Child; Dose-Response Relationship, Drug; Female; Fragile X Syndrome; Humans; Male; Pilot Projects; Prospective Studies; Severity of Illness Index; Social Behavior; Taurine; Treatment Outcome | 2013 |
Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Data Interpretation, Statistical; Disease Progression; Female; Humans; Longitudinal Studies; Male; Models, Statistical; Naltrexone; Narcotic Antagonists; Poisson Distribution; Risk-Taking; Taurine; Temperance; Treatment Outcome | 2013 |
Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder.
Topics: Acamprosate; Adolescent; Autistic Disorder; Child; Child, Preschool; Female; Humans; Male; Pilot Projects; Single-Blind Method; Social Behavior; Taurine; Treatment Outcome | 2014 |
Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Cross-Sectional Studies; Health Plan Implementation; Humans; Information Dissemination; Taurine; Treatment Outcome; United States; United States Substance Abuse and Mental Health Services Administration | 2014 |
What happens when people discontinue taking medications? Lessons from COMBINE.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Naltrexone; Patient Dropouts; Recurrence; Taurine | 2014 |
Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study).
Topics: Acamprosate; Adult; Aged; Alcoholism; Double-Blind Method; Ethanol; Female; Humans; Japan; Long-Term Care; Male; Middle Aged; Substance Withdrawal Syndrome; Taurine | 2015 |
Pain as a predictor of heavy drinking and any drinking lapses in the COMBINE study and the UK Alcohol Treatment Trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Behavior Therapy; Chronic Pain; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Pain Measurement; Recurrence; Taurine; Treatment Outcome | 2015 |
An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Body Mass Index; Decision Trees; Double-Blind Method; Humans; Middle Aged; Taurine; Treatment Outcome; United States | 2015 |
Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers.
Topics: Acamprosate; Administration, Oral; Cross-Over Studies; Drug Administration Schedule; Humans; Male; Tablets; Taurine; Therapeutic Equivalency; Young Adult | 2015 |
Therapist empathy, combined behavioral intervention, and alcohol outcomes in the COMBINE research project.
Topics: Acamprosate; Adaptation, Psychological; Affect; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Counseling; Empathy; Health Personnel; Humans; Middle Aged; Naltrexone; Taurine; Treatment Outcome | 2016 |
Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Reproducibility of Results; Reward; Taurine; Treatment Outcome | 2017 |
Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence.
Topics: Acamprosate; Adult; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Behavior Therapy; Double-Blind Method; Female; Humans; Male; Middle Aged; Naloxone; Narcotic Antagonists; Taurine; Time Factors; Treatment Outcome | 2017 |
Effectiveness of Psychoanalytic-Interactional Group Therapy vs. Behavioral Group Therapy in Routine Outpatient Treatment of Alcohol-Dependent Patients.
Topics: Acamprosate; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Disulfiram; Female; Humans; Male; Middle Aged; Naltrexone; Outpatients; Psychoanalytic Therapy; Psychotherapy, Group; Recurrence; Secondary Prevention; Taurine; Treatment Outcome | 2018 |
262 other study(ies) available for taurine and acamprosate
| Article | Year |
|---|---|
Possible association of erythema multiforme with acamprosate.
Topics: Acamprosate; Adult; Alcohol Deterrents; Drug Eruptions; Erythema Multiforme; Female; Humans; Taurine | 1992 |
GABA and nucleus accumbens glutamate neurotransmission modulate ethanol self-administration in rats.
Topics: 2-Amino-5-phosphonovalerate; Acamprosate; Animals; Azides; Benzodiazepines; Choice Behavior; Convulsants; Ethanol; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Glutamates; Infusions, Parenteral; Male; Nucleus Accumbens; Organophosphorus Compounds; Rats; Receptors, GABA-A; Receptors, Glutamate; Receptors, Neurotransmitter; Self Administration; Taurine | 1992 |
Acamprosate as cause of erythema multiforme contested.
Topics: Acamprosate; Alcoholism; Erythema Multiforme; Female; Herpes Genitalis; Humans; Liver Cirrhosis; Taurine; Vulvar Diseases | 1992 |
Triptosine, an L-5-hydroxytryptophan derivative, reduces alcohol consumption in alcohol-preferring rats.
Topics: 5-Hydroxytryptophan; Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Appetite; Brain; Dose-Response Relationship, Drug; Drug Combinations; Inosine; Male; Rats; Receptors, Serotonin; Serotonin; Taurine | 1992 |
Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats.
Topics: Acamprosate; Alcoholism; Animals; Brain Chemistry; Chromatography, High Pressure Liquid; Ethanol; gamma-Aminobutyric Acid; Male; Rats; Rats, Inbred Strains; Synaptosomes; Taurine; Tritium | 1992 |
Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour.
Topics: Acamprosate; Administration, Inhalation; Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Animals; Arousal; Cerebral Cortex; Diazepam; Dose-Response Relationship, Drug; Energy Metabolism; Ethanol; gamma-Aminobutyric Acid; Motor Activity; Oxygen Consumption; Rats; Receptors, GABA-A; Regional Blood Flow; Substance Withdrawal Syndrome; Taurine | 1991 |
Acamprosate, citalopram, and alcoholism.
Topics: Acamprosate; Alcoholism; Citalopram; Clinical Trials as Topic; gamma-Glutamyltransferase; Humans; Taurine | 1991 |
Acamprosate, citalopram, and alcoholism.
Topics: Acamprosate; Alcoholism; Citalopram; Humans; Patient Dropouts; Taurine | 1991 |
Determination of calcium acetylhomotaurinate in human plasma and urine by combined gas chromatography-negative-ion chemical ionization mass spectrometry.
Topics: Acamprosate; Adult; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Indicators and Reagents; Quality Control; Taurine | 1990 |
Application of an analytical method to calcium acetylhomotaurinate determination in urine.
Topics: Acamprosate; Animals; Chromatography, High Pressure Liquid; Dogs; Female; Injections, Intravenous; Spectrophotometry, Ultraviolet; Taurine | 1989 |
Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals.
Topics: Acamprosate; Animals; Dose-Response Relationship, Drug; Female; Macaca mulatta; Male; Self Administration; Substance-Related Disorders; Taurine | 1989 |
Noradrenaline and GABA brain receptors are co-involved in the voluntary intake of ethanol by rats.
Topics: Acamprosate; Alcohol Drinking; Animals; Bicuculline; Brain; Dibenzazepines; Male; Rats; Receptors, Adrenergic; Receptors, GABA-A; Taurine | 1987 |
Physicochemical, pharmacological and pharmacokinetic study of a new GABAergic compound, calcium acetylhomotaurinate.
Topics: Acamprosate; Animals; Blood-Brain Barrier; Corpus Striatum; gamma-Aminobutyric Acid; Male; Rats; Taurine | 1988 |
Similar antagonistic effects of Ca N-acetylhomotaurinate on depression of motor activity and lethality induced by acetaldehyde or ethanol.
Topics: Acamprosate; Acetaldehyde; Alcoholism; Amino Acids, Sulfur; Animals; Cations; Ethanol; Male; Mice; Motor Activity; Rats; Taurine | 1988 |
Determination of calcium acetylhomotaurinate by liquid chromatography with fluorimetric and electrochemical detection.
Topics: Acamprosate; Animals; Chromatography, High Pressure Liquid; Dogs; Electrochemistry; Hydrolysis; Mercaptoethanol; o-Phthalaldehyde; Spectrometry, Fluorescence; Taurine | 1987 |
A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved?
Topics: Acamprosate; Alcohol Drinking; Animals; Anticonvulsants; Brain; Calcium Chloride; Male; Rats; Receptors, GABA-A; Taurine | 1984 |
Comparative studies of Ca N-acetylhomotaurinate and Ca N-acetyltaurinate. I. Effects on the ionic transfer through the isolated human amnion.
Topics: Acamprosate; Amnion; Antimetabolites; Antiporters; Carrier Proteins; Chloride-Bicarbonate Antiporters; Diffusion; Female; Humans; In Vitro Techniques; Membranes; Pregnancy; Sodium-Hydrogen Exchangers; Sodium-Potassium-Chloride Symporters; Sodium-Potassium-Exchanging ATPase; Taurine | 1995 |
Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors.
Topics: Acamprosate; Action Potentials; Animals; Cerebral Cortex; Evoked Potentials; In Vitro Techniques; Male; Neurons; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Amino Acid; Synapses; Taurine | 1993 |
Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro.
Topics: Acamprosate; Alcohol Deterrents; Animals; Evoked Potentials; Glutamic Acid; Glycine; Hippocampus; In Vitro Techniques; Male; N-Methylaspartate; Neurons; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission; Taurine | 1996 |
Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Dose-Response Relationship, Drug; Ethanol; Injections, Intraperitoneal; Male; Rats; Rats, Wistar; Taurine; Time Factors | 1996 |
Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat.
Topics: Acamprosate; Alcohol Deterrents; Animals; Body Temperature; Drinking; Eating; Ethanol; Male; Motor Activity; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Taurine | 1996 |
Acamprosate and alcohol: III. Effects on alcohol discrimination in the rat.
Topics: Acamprosate; Alcohol Deterrents; Animals; Discrimination Learning; Discrimination, Psychological; Dizocilpine Maleate; Dose-Response Relationship, Drug; Ethanol; Excitatory Amino Acid Antagonists; Male; Rats; Rats, Wistar; Taurine | 1996 |
Interactions between ethanol and agents that act on the NMDA-type glutamate receptor.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Brain; Drug Interactions; Ethanol; Excitatory Amino Acid Antagonists; Humans; Ion Channels; Motivation; Piperidines; Receptors, N-Methyl-D-Aspartate; Taurine | 1996 |
International update: new findings on promising medications.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Cocaine; Comorbidity; Europe; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Taurine; United States | 1996 |
Alternatives to naltrexone in animal models.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Haplorhini; Humans; Naltrexone; Narcotic Antagonists; Rats; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine; Thyrotropin-Releasing Hormone | 1996 |
The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal.
Topics: Acamprosate; Alcohol Deterrents; Animals; Central Nervous System Depressants; Cerebellum; Convulsants; Ethanol; Hippocampus; Immunoblotting; In Situ Hybridization; Male; Oligonucleotide Probes; Pentylenetetrazole; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; RNA, Messenger; Substance Withdrawal Syndrome; Taurine | 1996 |
[Pharmacotherapy of alcoholism].
Topics: Acamprosate; Alcoholism; Female; Humans; Male; Substance-Related Disorders; Taurine | 1996 |
Time course of acamprosate action on operant ethanol self-administration after ethanol deprivation.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Conditioning, Operant; Dose-Response Relationship, Drug; Ethanol; Male; Motivation; Rats; Rats, Wistar; Self Administration; Substance Withdrawal Syndrome; Taurine | 1997 |
New drug treatments for alcohol problems: a critical appraisal.
Topics: Acamprosate; Alcoholism; Anti-Anxiety Agents; Buspirone; Dopamine Antagonists; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Taurine | 1997 |
Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Central Nervous System Depressants; Conditioning, Operant; Dose-Response Relationship, Drug; Ethanol; Male; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Taurine | 1998 |
Treating alcohol dependence. Acamprostate is another drug to help maintain abstinence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Taurine | 1997 |
Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons.
Topics: Acamprosate; Alcohol Deterrents; Animals; GABA-B Receptor Antagonists; Male; Membrane Potentials; Neurons; Nucleus Accumbens; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Receptors, GABA-B; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission; Taurine | 1998 |
Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain.
Topics: Acamprosate; Alcohol Deterrents; Animals; Brain; Culture Techniques; Male; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Spermidine; Synaptic Membranes; Taurine | 1998 |
Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Cerebral Cortex; Culture Techniques; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Male; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Taurine | 1998 |
Teaching the brain to take drugs.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Addictive; Brain; Cocaine; Cocaine-Related Disorders; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Rats; Receptors, Glutamate; Substance-Related Disorders; Synaptic Transmission; Taurine | 1998 |
Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats.
Topics: Acamprosate; Alanine; Alcohol Deterrents; Alcoholism; Animals; Arginine; Aspartic Acid; Chromatography, High Pressure Liquid; gamma-Aminobutyric Acid; Glutamic Acid; Male; Nucleus Accumbens; Rats; Rats, Wistar; Taurine | 1998 |
The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats.
Topics: Acamprosate; Alcohol Deterrents; Analgesics, Opioid; Animals; Conditioning, Psychological; Drug Interactions; Male; Morphine; Naloxone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Recurrence; Spatial Behavior; Substance Withdrawal Syndrome; Taurine | 1998 |
Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress.
Topics: Acamprosate; Animals; Drug Interactions; Drug Tolerance; Food Deprivation; Heroin; Heroin Dependence; Male; Morphine; Narcotics; Rats; Rats, Sprague-Dawley; Recurrence; Self Administration; Stress, Physiological; Taurine | 1998 |
[Medical treatment of alcohol dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine | 1998 |
New treatments for alcohol dependency better than old.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Taurine | 1999 |
The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cost-Benefit Analysis; Economics, Pharmaceutical; Germany; Humans; Models, Economic; Recurrence; Taurine | 1998 |
Prevention of relapse in alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family; Humans; Naltrexone; Narcotic Antagonists; Recurrence; Self-Help Groups; Taurine | 1999 |
Acamprosate decreases the hypermotility during repeated ethanol withdrawal.
Topics: Acamprosate; Alcohol Deterrents; Animals; Central Nervous System Depressants; Ethanol; Glutamic Acid; Male; Motor Activity; Nucleus Accumbens; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Taurine | 1999 |
Medical allies against alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Taurine | 1999 |
[Glutamate receptor agonists and alcohol dependence. Preclinical findings].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Chronic Disease; Disease Models, Animal; Humans; Memantine; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Taurine | 1999 |
Occurrence and management of depression in the context of naltrexone treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Comorbidity; Depressive Disorder; Diagnosis, Dual (Psychiatry); Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Taurine | 1999 |
Determination of homotaurine as impurity in calcium acamprosate by capillary zone electrophoresis.
Topics: Acamprosate; Calibration; Electrolytes; Electrophoresis, Capillary; Fluorescamine; Injections; Linear Models; Quality Control; Reproducibility of Results; Spectrophotometry, Ultraviolet; Taurine | 1999 |
Acamprosate does not antagonise the discriminative stimulus properties of amphetamine and morphine in rats.
Topics: Acamprosate; Alcohol Deterrents; Amphetamine; Animals; Central Nervous System Stimulants; Discrimination Learning; Dizocilpine Maleate; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Male; Morphine; Narcotics; Rats; Rats, Sprague-Dawley; Reaction Time; Taurine | 1999 |
Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze.
Topics: Acamprosate; Alcohol Deterrents; Animals; Anxiety; Central Nervous System Depressants; Ethanol; Exploratory Behavior; Male; Mice; Naltrexone; Substance Withdrawal Syndrome; Taurine | 2000 |
Acamprosate. Pharmacoeconomic implications of therapy.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cost-Benefit Analysis; Costs and Cost Analysis; Humans; Taurine | 1999 |
Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons.
Topics: Acamprosate; Alcohol Deterrents; Animals; Cells, Cultured; Central Nervous System Depressants; Electrophysiology; Ethanol; Excitatory Amino Acid Agonists; In Vitro Techniques; N-Methylaspartate; Neostriatum; Neurons; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Spermine; Taurine; Transfection | 2000 |
Pharmacological validation of a new animal model of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Naltrexone; Narcotic Antagonists; Rats; Reproducibility of Results; Secondary Prevention; Self Administration; Substance Withdrawal Syndrome; Taurine | 2000 |
[Efficient prevention of relapse with acamprosate].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Recurrence; Taurine | 2000 |
An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Belgium; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Luxembourg; Male; Middle Aged; Psychotherapy; Taurine; Treatment Outcome | 2000 |
[The neuroprotective effect of the glutamate antagonist acamprosate following experimental cerebral ischemia. A study with the lipid peroxidase inhibitor u-101033e].
Topics: Acamprosate; Alcohol Deterrents; Anesthetics, Intravenous; Animals; Brain Ischemia; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Fentanyl; Lipid Peroxidation; Male; Neuroprotective Agents; Peroxidase; Pyrimidines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Taurine | 2000 |
Acamprosate inhibits Ca2+ influx mediated by NMDA receptors and voltage-sensitive Ca2+ channels in cultured rat mesencephalic neurones.
Topics: Acamprosate; Alcohol Deterrents; Animals; Calcium; Calcium Channels; Cells, Cultured; Mesencephalon; Neurons; omega-Conotoxins; Rats; Receptors, N-Methyl-D-Aspartate; Taurine | 2000 |
Can this pill stop you from hitting the bottle?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Counseling; Humans; Motivation; Naltrexone; Narcotic Antagonists; Taurine; United States | 2001 |
Effects of acamprosate on ethanol-seeking and self-administration in the rat.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Male; Rats; Rats, Long-Evans; Reinforcement, Psychology; Self Administration; Taurine | 2001 |
Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Taurine | 2001 |
The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801.
Topics: Acamprosate; Alcohol Deterrents; Animals; Brain; Cell Line; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; N-Methylaspartate; Neurons; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Taurine; Xenopus | 2001 |
Combined behavioral and pharmacologic treatments of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine | 2001 |
Does the alcoholic's remedy come in a pill?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Excitatory Amino Acid Antagonists; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Ondansetron; Patient Compliance; Serotonin Antagonists; Social Support; Taurine; United States | 2001 |
Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain.
Topics: Acamprosate; Alcohol Deterrents; Animals; Calcium Radioisotopes; Cell Death; Cells, Cultured; Ethanol; Glutamic Acid; L-Lactate Dehydrogenase; Neocortex; Neuroprotective Agents; Potassium; Rats; Rats, Sprague-Dawley; Taurine | 2001 |
Addiction medicine for the primary care physician.
Topics: Acamprosate; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Antidepressive Agents, Tricyclic; Disulfiram; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Primary Health Care; Recurrence; Risk Factors; Severity of Illness Index; Substance-Related Disorders; Taurine; Treatment Outcome | 2001 |
Effects of acamprosate on sensitization to the locomotor-stimulant effects of alcohol in mice selectively bred for high and low alcohol preference.
Topics: Acamprosate; Alcohol Drinking; Animals; Drug Interactions; Ethanol; Female; Genotype; Male; Mice; Mice, Inbred Strains; Motor Activity; Selection, Genetic; Taurine | 2001 |
Effects of acamprosate and scopolamine on the working memory of rats in a three-panel runway task.
Topics: Acamprosate; Alcohol Deterrents; Animals; Drug Interactions; Male; Memory; Muscarinic Antagonists; Rats; Rats, Wistar; Scopolamine; Taurine | 2001 |
Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol.
Topics: Acamprosate; Adaptation, Physiological; Alcohol Deterrents; Alcoholism; Amygdala; Animals; Behavior, Animal; Brain; Cannabinoid Receptor Modulators; Conditioning, Operant; Corticosterone; Ethanol; Frontal Lobe; Gene Expression Profiling; Kinetics; Male; Oligonucleotide Array Sequence Analysis; Rats; Rats, Wistar; Taurine; Transcriptional Activation; Up-Regulation | 2002 |
Investigation of the therapeutic efficacy of a taurine analogue during the initial stages of ethanol detoxification: preliminary studies in chronic alcohol abusers.
Topics: Acamprosate; Alcoholism; Amino Acids; Chlordiazepoxide; Chronic Disease; Ethanol; GABA Modulators; Glutamic Acid; Humans; Molecular Structure; Taurine | 2000 |
Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Central Nervous System Depressants; Dopamine; Dose-Response Relationship, Drug; Ethanol; Male; Nucleus Accumbens; Rats; Rats, Long-Evans; Taurine | 2002 |
[An analysis of ionic flow of spontaneous slow action potential of guinea pig aortic vestibule].
Topics: Acamprosate; Action Potentials; Animals; Calcium; Calcium Channels; Female; Guinea Pigs; In Vitro Techniques; Male; Potassium; Sodium; Sodium Channels; Taurine | 2000 |
Drug treatments for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Substance Withdrawal Syndrome; Taurine | 2002 |
Central nervous system mechanisms in alcohol relapse.
Topics: Acamprosate; Alcoholism; Animals; Behavior; Central Nervous System; Corticotropin-Releasing Hormone; Disease Models, Animal; Environment; Ethanol; Food Preferences; Humans; Mice; Neurons; Rats; Recurrence; Reinforcement, Psychology; Stress, Physiological; Taurine | 2002 |
Potential neuroprotective effects of acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Brain; Humans; Neuroprotective Agents; Substance Withdrawal Syndrome; Synaptic Transmission; Taurine | 2002 |
Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat.
Topics: Acamprosate; Animals; Animals, Newborn; Culture Media; Female; Hippocampus; Male; N-Methylaspartate; Organ Culture Techniques; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Spermidine; Taurine | 2002 |
Acamprosate decreases the induction of tolerance and physical dependence in morphine-treated mice.
Topics: Acamprosate; Animals; Drug Tolerance; Male; Mice; Morphine; Morphine Dependence; Pain Measurement; Taurine | 2002 |
Effects of acamprosate and some polyamine site ligands of NMDA receptor on short-term memory in rats.
Topics: Acamprosate; Administration, Oral; Animals; Biguanides; Dose-Response Relationship, Drug; Drug Interactions; Male; Memory, Short-Term; Motor Activity; Piperidines; Polyamines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Sleep; Spermidine; Taurine | 2002 |
Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Ambulatory Care; Cognitive Behavioral Therapy; Cohort Studies; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Secondary Prevention; Taurine | 2002 |
Disposition of acamprosate in the rat: influence of probenecid.
Topics: Acamprosate; Animals; Drug Interactions; Injections, Intravenous; Male; Metabolic Clearance Rate; Probenecid; Rats; Rats, Wistar; Taurine | 2002 |
Acamprosate reduces context-dependent ethanol effects.
Topics: Acamprosate; Animals; Cues; Dose-Response Relationship, Drug; Ethanol; Male; Motor Activity; Rats; Rats, Wistar; Taurine | 2002 |
Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus.
Topics: Acamprosate; Animals; Animals, Newborn; Calcium Signaling; Dizocilpine Maleate; Ethanol; Female; Hippocampus; Male; Organ Culture Techniques; Piperidines; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Taurine | 2002 |
The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction.
Topics: Acamprosate; Adult; Alcoholism; Analysis of Variance; Chi-Square Distribution; Europe; Female; Forecasting; Humans; Male; Middle Aged; Prospective Studies; Regression Analysis; Secondary Prevention; Social Support; Taurine; Temperance | 2002 |
Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors.
Topics: Acamprosate; Animals; Binding Sites; Cycloleucine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Male; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Taurine | 2002 |
The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine.
Topics: Acamprosate; Alcohol Deterrents; Animals; Cocaine; Conditioning, Operant; Dose-Response Relationship, Drug; Ethanol; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Morphine; Secondary Prevention; Taurine | 2003 |
Local acamprosate modulates dopamine release in the rat nucleus accumbens through NMDA receptors: an in vivo microdialysis study.
Topics: Acamprosate; Alcohol Deterrents; Animals; Dopamine; Dose-Response Relationship, Drug; Male; Microdialysis; Nucleus Accumbens; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Taurine; Time Factors | 2003 |
[Deficits in preventing recurrence in alcoholic patients. Withdrawal--and immediately back to the bottle].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Clinical Trials as Topic; Combined Modality Therapy; Follow-Up Studies; Humans; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Taurine | 2003 |
Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods.
Topics: Acamprosate; Animals; Ethanol; Excitatory Amino Acids; Hippocampus; Male; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Taurine | 2003 |
Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats.
Topics: Acamprosate; Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethanol; Male; Naltrexone; Rats; Rats, Wistar; Taurine; Temperance | 2003 |
Physicians' opinions about medications to treat alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Attitude of Health Personnel; Clinical Competence; Disulfiram; Health Care Surveys; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2003 |
Acamprosate does not induce a conditioned place preference and reveals no state-dependent effects in this paradigm.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Conditioning, Classical; Male; Movement; Rats; Rats, Sprague-Dawley; Taurine | 2003 |
[Preventing recurrence after alcohol withdrawal treatment with drugs. Reducing the drive to drink].
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Humans; Male; Middle Aged; Motivation; Psychotherapy; Secondary Prevention; Taurine; Temperance | 2003 |
The effect of acamprosate on the development of morphine-induced behavioral sensitization in rats.
Topics: Acamprosate; Alcohol Deterrents; Animals; Behavior, Animal; Drug Administration Schedule; Drug Interactions; Morphine; Motor Activity; Narcotics; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Stereotyped Behavior; Taurine | 2003 |
A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Male; Pilot Projects; Severity of Illness Index; Surveys and Questionnaires; Taurine; Temperance; Time Factors; Treatment Outcome; Vocabulary | 2003 |
The anti-craving taurine derivative acamprosate: failure to extinguish morphine conditioned place preference.
Topics: Acamprosate; Alcohol Deterrents; Animals; Conditioning, Classical; Male; Mice; Mice, Inbred C57BL; Morphine; Taurine | 2003 |
New pharmacotherapies for alcohol dependence: are they being used and what do they cost?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Australia; Humans; Naltrexone; Taurine; Treatment Refusal | 2003 |
NR2B subunit selective NMDA antagonists inhibit neurotoxic effect of alcohol-withdrawal in primary cultures of rat cortical neurones.
Topics: Acamprosate; Alcohol Deterrents; Animals; Calcium; Cells, Cultured; Cerebral Cortex; Clone Cells; Cytosol; Excitatory Amino Acid Antagonists; Neurons; Rats; Receptors, N-Methyl-D-Aspartate; Recombinant Proteins; Substance Withdrawal Syndrome; Taurine | 2004 |
Acamprosate blocks the increase in dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus.
Topics: Acamprosate; Animals; Dopamine; Dopamine Antagonists; Excitatory Amino Acid Agonists; Extracellular Space; Hippocampus; Male; Microdialysis; N-Methylaspartate; Nucleus Accumbens; Rats; Rats, Wistar; Stereotaxic Techniques; Stimulation, Chemical; Taurine | 2003 |
[Psychosocial treatment plus drug prophylaxis. Fewer recurrences after alcohol withdrawal].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Ethanol; Humans; Randomized Controlled Trials as Topic; Secondary Prevention; Socioenvironmental Therapy; Substance Withdrawal Syndrome; Taurine; Temperance | 2003 |
Effect of the combination of naltrexone and acamprosate on alcohol intake in mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Taurine | 2004 |
Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support.
Topics: Acamprosate; Adult; Alcoholism; Analysis of Variance; Confidence Intervals; Female; Humans; Linear Models; Male; Middle Aged; Prospective Studies; Quality of Life; Social Support; Surveys and Questionnaires; Taurine | 2004 |
Does acamprosate improve reduction of drinking as well as aiding abstinence?
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Humans; Secondary Prevention; Taurine; Temperance | 2003 |
Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Topics: Acamprosate; Analgesics, Opioid; Animals; Antidepressive Agents, Second-Generation; Avoidance Learning; Buprenorphine; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Implants; Fluoxetine; Lisuride; Male; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Substance Withdrawal Syndrome; Taurine | 2005 |
Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network.
Topics: Acamprosate; Aging; Alcohol Deterrents; Animals; Animals, Newborn; Hypoglossal Nerve; N-Methylaspartate; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Receptors, N-Methyl-D-Aspartate; Respiratory Mechanics; Taurine | 2004 |
Synthesis and assessment of [11C]acetylhomotaurine as an imaging agent for the study of the pharmacodynamic properties of acamprosate by positron emission tomography.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Brain; Carbon Radioisotopes; Humans; Isotope Labeling; Male; Metabolic Clearance Rate; Mice; Positron-Emission Tomography; Rabbits; Radiopharmaceuticals; Taurine; Tissue Distribution; Treatment Outcome | 2004 |
The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats.
Topics: Acamprosate; Animals; Choice Behavior; Ethanol; Male; Memantine; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Saccharin; Substance Withdrawal Syndrome; Sweetening Agents; Taurine | 2004 |
Assessment and modulation of acamprosate intestinal absorption: comparative studies using in situ, in vitro (CACO-2 cell monolayers) and in vivo models.
Topics: Acamprosate; Animals; Caco-2 Cells; Cell Membrane; Electric Impedance; Humans; Intestinal Absorption; Male; Rats; Rats, Wistar; Taurine | 2004 |
The mosaic of addiction.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior, Addictive; Disease Models, Animal; Endorphins; Ethanol; Euphoria; Humans; Naltrexone; Receptors, Dopamine D2; Receptors, Opioid; Secondary Prevention; Taurine | 2004 |
[Acamprosate--new preclinical research aspects].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Brain; Drug Evaluation, Preclinical; Ethanol; Humans; Neuroprotective Agents; Rats; Receptors, N-Methyl-D-Aspartate; Research; Taurine | 2003 |
Effect of neramexane on ethanol dependence and reinforcement.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Central Nervous System Depressants; Conditioning, Operant; Cyclopentanes; Ethanol; Male; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Reinforcement, Psychology; Seizures; Substance Withdrawal Syndrome; Taurine | 2004 |
Ask the doctor. I need to quit drinking, but don't think I can do it on my own. Can I use a drug like Antabuse even though I have heart disease?
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Contraindications; Disulfiram; Heart Diseases; Humans; Naltrexone; Taurine | 2004 |
Acamprosate campral for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Diarrhea; Disulfiram; Drug Therapy, Combination; Humans; Naltrexone; Taurine | 2005 |
The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Amino Acid Transport System X-AG; Animals; Biological Clocks; Cell Cycle Proteins; Cocaine; Cocaine-Related Disorders; Glutamic Acid; Humans; Mice; Nuclear Proteins; Period Circadian Proteins; Taurine; Time Factors; Transcription Factors | 2005 |
Effect of acamprosate on neonatal excitotoxic cortical lesions in in utero alcohol-exposed hamsters.
Topics: Acamprosate; Alcohol Deterrents; Animals; Animals, Newborn; Central Nervous System Depressants; Cerebral Cortex; Cricetinae; Dose-Response Relationship, Drug; Drug Interactions; Ethanol; Female; Ibotenic Acid; Male; Pregnancy; Prenatal Exposure Delayed Effects; Taurine | 2005 |
Anti-craving drugs acamprosate and naloxone do not reduce expression of morphine conditioned place preference in isolated and group-housed rats.
Topics: Acamprosate; Alcohol Deterrents; Analysis of Variance; Animals; Behavior, Animal; Conditioning, Operant; Drug Interactions; Locomotion; Male; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Rats; Rats, Sprague-Dawley; Social Isolation; Spatial Behavior; Taurine | 2005 |
The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Conditioning, Operant; Cues; Cyclopentanes; Extinction, Psychological; Injections, Intraperitoneal; Male; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Recurrence; Taurine | 2005 |
[The pharmacologic treatment of the alcohol dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2004 |
Repeated-testing of place preference expression for evaluation of anti-craving-drug effects.
Topics: Acamprosate; Alcohol Deterrents; Analgesics, Opioid; Anesthetics, Local; Animals; Behavior, Animal; Cocaine; Conditioning, Psychological; Drug Evaluation, Preclinical; Male; Morphine; Naloxone; Narcotic Antagonists; Opioid-Related Disorders; Rats; Rats, Sprague-Dawley; Taurine | 2005 |
Acamprosate involvement in triacylglycerol hydrolysis and transacylation with cholesterol in chronically ethanol-drinking rats.
Topics: Acamprosate; Acylation; Alcohol Deterrents; Alcohol Drinking; Animals; Cholesterol; Ethanol; Hydrolysis; Male; Rats; Rats, Wistar; Sterol O-Acyltransferase; Taurine; Triglycerides | 2004 |
New drug released for alcohol dependency.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Taurine | 2005 |
Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; beta-Endorphin; Brain; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Ethanol; Female; Genetic Predisposition to Disease; Opioid Peptides; Rats; Taurine; Treatment Outcome; Up-Regulation | 2005 |
A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment.
Topics: Acamprosate; Adult; Alcoholism; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neurosecretory Systems; Secondary Prevention; Sex Characteristics; Taurine | 2005 |
The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system.
Topics: Acamprosate; Acute Disease; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Caudate Nucleus; Cell Count; Choice Behavior; Dopamine; Limbic System; Male; Motivation; Nucleus Accumbens; Putamen; Rats; Receptors, Dopamine D2; Self Administration; Taurine | 2005 |
Production of reactive oxygen species following acute ethanol or acetaldehyde and its reduction by acamprosate in chronically alcoholized rats.
Topics: Acamprosate; Acetaldehyde; Alcohol Deterrents; Alcoholism; Animals; Disease Models, Animal; Ethanol; Gentisates; Hippocampus; Hydroxybenzoates; Hydroxyl Radical; Male; Microdialysis; Rats; Rats, Wistar; Salicylic Acid; Substance Withdrawal Syndrome; Taurine; Time Factors | 2005 |
Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry.
Topics: Academies and Institutes; Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Cooperative Behavior; Cross-Cultural Comparison; Disulfiram; Drug Approval; Drug Industry; Drugs, Investigational; Evidence-Based Medicine; Humans; Interprofessional Relations; Naltrexone; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Taurine | 2005 |
Drug treatment for alcoholism today.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Disulfiram; Fructose; Humans; Naltrexone; Substance Withdrawal Syndrome; Taurine; Topiramate | 2005 |
Choosing pharmacotherapies for the COMBINE Study--process and procedures: an investigational approach to combination pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Humans; Naltrexone; Narcotic Antagonists; Research Design; Taurine; Treatment Outcome | 2005 |
The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Guidelines as Topic; Health Personnel; Humans; Naltrexone; Narcotic Antagonists; Observer Variation; Surveys and Questionnaires; Taurine; Terminology as Topic | 2005 |
N-methyl-D-aspartate and group I metabotropic glutamate receptors are involved in the expression of ethanol-induced sensitization in mice.
Topics: Acamprosate; Alcoholism; Animals; Brain; Cyclopentanes; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Synergism; Ethanol; Glutamic Acid; Male; Mice; Motor Activity; N-Methylaspartate; Pyridines; Quinolines; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Stereotyped Behavior; Synaptic Transmission; Taurine; Thiazoles | 2006 |
New alcohol abuse drugs emerging. Anti-craving meds are finally here to treat alcohol dependence, recognized as a disease of the brain.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Taurine | 2005 |
New drugs 06, part I.
Topics: Acamprosate; Adenine Nucleotides; Alcohol Deterrents; Amyloid; Analgesics, Non-Narcotic; Anti-HIV Agents; Antifungal Agents; Antineoplastic Agents; Aptamers, Nucleotide; Arabinonucleosides; Azabicyclo Compounds; Benzofurans; Clofarabine; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Echinocandins; Exenatide; Fibroblast Growth Factor 7; Guanine; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Lipopeptides; Lipoproteins; Macular Degeneration; Micafungin; omega-Conotoxins; Patient Education as Topic; Peptides; Peptides, Cyclic; Piperazines; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Stomatitis; Taurine; Tetrahydroisoquinolines; Urinary Incontinence; Venoms | 2006 |
Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Bupropion; Dopamine Uptake Inhibitors; Female; Health Care Surveys; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Substance-Related Disorders; Taurine; Tobacco Use Disorder | 2006 |
Tinnitus. Overcoming the noise.
Topics: Acamprosate; Hair Cells, Auditory; Humans; Hypnotics and Sedatives; Taurine; Tinnitus | 2006 |
The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Attitude to Health; Disulfiram; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychological Theory; Psychology; Psychotherapy; Taurine | 2006 |
Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Appetitive Behavior; Dose-Response Relationship, Drug; Drinking; Hunger; Injections, Intraperitoneal; Male; Mice; Mice, Inbred Strains; Naltrexone; Reinforcement Schedule; Taurine; Thirst | 2006 |
Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; beta-Endorphin; Biomarkers; Female; Humans; Male; Middle Aged; Placebos; Rats; Taurine | 2006 |
Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: an in vivo study in rats.
Topics: Acamprosate; Alcohol Deterrents; Animals; Dose-Response Relationship, Drug; Drug Administration Routes; Male; Rats; Rats, Wistar; Taurine | 2006 |
[Maintaining abstinence after alcohol detoxification].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Ambulatory Care; Behavior Therapy; Clinical Protocols; Cognitive Behavioral Therapy; Disulfiram; Follow-Up Studies; Humans; Naltrexone; Patient Care Planning; Psychoanalytic Therapy; Psychotherapy, Group; Psychotropic Drugs; Social Support; Taurine; Temperance | 2006 |
Attenuation of cocaine-induced reinstatement of cocaine conditioned place preference by acamprosate.
Topics: Acamprosate; Animals; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Extinction, Psychological; GABA Modulators; Male; Mice; Mice, Inbred C57BL; Secondary Prevention; Taurine | 2006 |
Extended-release intramuscular naltrexone: a viewpoint by Henry R Kranzler.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Delayed-Action Preparations; Disulfiram; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Taurine | 2006 |
Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2006 |
Is acamprosate use in alcohol dependence treatment reflected in improved subjective health status outcomes beyond cognitive behavioural therapy alone?.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Health Status; Humans; Incidence; Male; Prevalence; Psychology; Surveys and Questionnaires; Taurine; Temperance; Treatment Outcome | 2006 |
Influence of age at drinking onset on the alcohol deprivation effect and stress-induced drinking in female rats.
Topics: Acamprosate; Age of Onset; Aging; Alcohol Deterrents; Alcohol Drinking; Animals; Central Nervous System Depressants; Electroshock; Ethanol; Female; Rats; Rats, Wistar; Stress, Psychological; Substance Withdrawal Syndrome; Swimming; Taurine | 2007 |
[Drugs against alcohol abuse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Drug Evaluation; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2006 |
Alcohol dependence and pharmacologic treatment. Introduction.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Humans; Naltrexone; Taurine; United States | 2007 |
Schizophrenia and co-occurring substance use disorder.
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Humans; Ill-Housed Persons; Male; Naltrexone; Schizophrenia; Substance-Related Disorders; Taurine | 2007 |
Consideration of acamprosate for treatment of amyotrophic lateral sclerosis.
Topics: Acamprosate; Animals; Calcium; Disease Models, Animal; Humans; Mice; Motor Neuron Disease; Motor Neurons; Taurine | 2007 |
Acamprosate and primitive reflexes.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain Stem; Humans; Male; Middle Aged; Reflex; Taurine | 2007 |
Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Conditioning, Operant; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Naltrexone; Nitriles; Receptors, Dopamine D3; Taurine; Tetrahydroisoquinolines | 2007 |
Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Genetic Predisposition to Disease; Germany; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychotherapy; Randomized Controlled Trials as Topic; Recurrence; Spain; Taurine; Treatment Outcome | 2008 |
Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats.
Topics: Acamprosate; Alcohol Deterrents; Animals; Behavior, Addictive; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Cues; Dose-Response Relationship, Drug; Extinction, Psychological; Male; Motor Activity; Rats; Rats, Sprague-Dawley; Recurrence; Self Administration; Taurine | 2007 |
The effect of acamprosate on alcohol and food craving in patients with alcohol dependence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Body Mass Index; Cognitive Behavioral Therapy; Cohort Studies; Combined Modality Therapy; Feeding and Eating Disorders; Female; Food; GABA Modulators; Humans; Lorazepam; Male; Middle Aged; Psychiatric Status Rating Scales; Socioeconomic Factors; Taurine; Thiamine | 2008 |
New therapies for alcohol dependence open options for office-based treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family Practice; Fructose; Humans; Naltrexone; Taurine; Topiramate | 2007 |
NMDA receptor blockade: a novel avenue for tobacco intervention?
Topics: Acamprosate; Central Nervous System Stimulants; Humans; Memantine; Models, Biological; Models, Theoretical; Neurons; Nicotiana; Nicotine; Prefrontal Cortex; Receptors, N-Methyl-D-Aspartate; Smoking Cessation; Taurine | 2008 |
Somatic configuration: a model for an integrated approach to the understanding of disease.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Bayes Theorem; Cognitive Behavioral Therapy; Decision Trees; Humans; Models, Theoretical; Outcome Assessment, Health Care; Prognosis; Queensland; Secondary Prevention; Substance Abuse Treatment Centers; Taurine | 2007 |
The application of machine learning techniques as an adjunct to clinical decision making in alcohol dependence treatment.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Artificial Intelligence; Bayes Theorem; Cognitive Behavioral Therapy; Decision Support Systems, Clinical; Decision Trees; Hawaii; Humans; Outcome Assessment, Health Care; Pilot Projects; Secondary Prevention; Taurine | 2007 |
Effect of chronic acamprosate treatment on voluntary alcohol intake and beta-endorphin plasma levels in rats selectively bred for high alcohol preference.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; beta-Endorphin; Disease Models, Animal; Ethanol; Female; Rats; Taurine; Time Factors | 2008 |
Effects of acamprosate on neuronal receptors and ion channels expressed in Xenopus oocytes.
Topics: Acamprosate; Alcohol Deterrents; Animals; Dose-Response Relationship, Drug; Ethanol; Ion Channels; Oocytes; Receptor, Metabotropic Glutamate 5; Receptor, Muscarinic M1; Receptors, GABA-A; Receptors, Glycine; Receptors, Metabotropic Glutamate; Receptors, Neurotransmitter; Sodium Channels; Taurine; TRPV Cation Channels; Xenopus laevis | 2008 |
A microdialysis study of extracellular levels of acamprosate and naltrexone in the rat brain following acute and repeated administration.
Topics: Acamprosate; Alcohol Deterrents; Animals; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Extracellular Fluid; Frontal Lobe; Injections, Intraperitoneal; Male; Metabolic Clearance Rate; Microdialysis; Naltrexone; Rats; Rats, Long-Evans; Taurine | 2008 |
From the neurobiologic basis of alcohol dependency to pharmacologic treatment strategies: bridging the knowledge gap.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Psychotherapy; Receptors, Dopamine; Receptors, GABA; Receptors, Opioid; Taurine | 2008 |
Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Analysis of Variance; Animals; Behavior, Animal; Central Nervous System Depressants; Choice Behavior; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Ethanol; Excitatory Amino Acid Antagonists; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Reflex; Self Administration; Sex Factors; Taurine | 2008 |
Effects of naltrexone and acamprosate on alcohol-induced NGFI-A expression in mouse brain.
Topics: Acamprosate; Amygdala; Animals; Brain; Early Growth Response Protein 1; Ethanol; Male; Mice; Naltrexone; Taurine | 2008 |
Investigation of the relationship between in vitro and in vivo release behaviors of acamprosate from enteric-coated tablets.
Topics: Acamprosate; Administration, Oral; Alcohol Deterrents; Animals; Biological Availability; Buffers; Chemistry, Pharmaceutical; Dogs; Hydrogen-Ion Concentration; Intestinal Absorption; Male; Permeability; Reproducibility of Results; Solubility; Tablets, Enteric-Coated; Taurine | 2008 |
Acamprosate attenuates the handling induced convulsions during alcohol withdrawal in Swiss Webster mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Withdrawal Seizures; Alcohols; Analysis of Variance; Animals; Anticonvulsants; Antidotes; Behavior, Animal; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Fomepizole; Handling, Psychological; Male; Mice; Pyrazoles; Taurine | 2008 |
Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Male; Models, Animal; Naltrexone; Narcotic Antagonists; Rats; Rats, Long-Evans; Rats, Wistar; Taurine; Time Factors | 2008 |
Aminomethylpiperazines as selective urotensin antagonists.
Topics: Acamprosate; Animals; Aorta; Chemistry, Pharmaceutical; Drug Design; Humans; Hypertension; Models, Chemical; Piperazines; Rats; Receptors, Opioid, kappa; Structure-Activity Relationship; Taurine; Urotensins | 2008 |
[Pharmacotherapy of alcohol dependence].
Topics: Acamprosate; Adrenergic beta-Antagonists; Alcohol Deterrents; Alcoholism; Ambulatory Care; Anticonvulsants; Benzodiazepines; Chlormethiazole; Ethanol; Family Practice; Humans; Naltrexone; Patient Admission; Secondary Prevention; Substance Withdrawal Syndrome; Taurine | 2008 |
Acute effects of acamprosate and MPEP on ethanol Drinking-in-the-Dark in male C57BL/6J mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Darkness; Disease Models, Animal; Dose-Response Relationship, Drug; Food Deprivation; Male; Mice; Mice, Inbred C57BL; Pyridines; Receptors, Metabotropic Glutamate; Signal Transduction; Taurine | 2008 |
Analysis of acamprosate in beagle dog plasma by LC-MS-MS.
Topics: Acamprosate; Alcohol Deterrents; Animals; Calibration; Chromatography, High Pressure Liquid; Chromatography, Liquid; Dogs; Freezing; Male; Mass Spectrometry; Quality Control; Reference Standards; Solutions; Spectrometry, Mass, Electrospray Ionization; Tablets, Enteric-Coated; Taurine | 2008 |
Preserved DNA from past clinical trials yields new information about a subtype of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Alleles; Combined Modality Therapy; Drug Therapy, Combination; Genetic Carrier Screening; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Prognosis; Psychotherapy; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Taurine; Treatment Outcome | 2008 |
Successful acamprosate treatment of alcohol dependence in schizophrenia.
Topics: Acamprosate; Aged; Alcohol Deterrents; Alcoholism; Comorbidity; Female; Humans; Schizophrenia; Taurine; Treatment Outcome | 2008 |
Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Delayed-Action Preparations; Disulfiram; Drug Costs; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Humans; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Osteopathic Medicine; Physicians; Physicians, Family; Psychiatry; Taurine; United States | 2009 |
The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats.
Topics: Acamprosate; Alcohol Deterrents; Animals; Anxiety; Behavior, Animal; Central Nervous System Depressants; Ethanol; Excitatory Amino Acid Antagonists; Male; Memantine; Pyridines; Quinolines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, Glutamate; Receptors, Metabotropic Glutamate; Substance Withdrawal Syndrome; Taurine; Thiazoles | 2008 |
Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Body Weight; Conditioning, Operant; Data Interpretation, Statistical; Male; Naltrexone; Rats; Rats, Long-Evans; Sucrose; Taste; Taurine | 2009 |
Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychotherapy; Taurine; Treatment Outcome | 2009 |
Cue-induced alcohol-seeking behaviour is reduced by disrupting the reconsolidation of alcohol-related memories.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Animals; Anisomycin; Behavior, Addictive; Behavior, Animal; Conditioning, Operant; Cues; Dizocilpine Maleate; Ethanol; Male; Memory; Mental Recall; Protein Synthesis Inhibitors; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Self Administration; Taurine | 2009 |
Treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Fructose; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Taurine; Topiramate; Vitamins | 2009 |
Glycine receptors in the nucleus accumbens involved in the ethanol intake-reducing effect of acamprosate.
Topics: Acamprosate; Alcohol Drinking; Animals; Dopamine; Ethanol; Male; Microinjections; Nucleus Accumbens; Protein Binding; Rats; Rats, Wistar; Receptors, Glycine; Taurine | 2010 |
Glycine receptors involved in acamprosate's modulation of accumbal dopamine levels: an in vivo microdialysis study.
Topics: Acamprosate; Animals; Dopamine; Extracellular Fluid; Injections, Intraperitoneal; Injections, Intraventricular; Male; Microdialysis; Nucleus Accumbens; Rats; Rats, Wistar; Receptors, Glycine; Taurine | 2010 |
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism; Anticonvulsants; Baclofen; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; France; Fructose; Health Status; Humans; Naltrexone; Psychotherapy; Randomized Controlled Trials as Topic; Secondary Prevention; Self-Help Groups; Social Support; Taurine; Temperance; Topiramate; Treatment Outcome | 2009 |
Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Odds Ratio; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome; United States | 2010 |
The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Diffusion of Innovation; Follow-Up Studies; Health Services Research; Humans; Naltrexone; Nitrosamines; Organizational Culture; Organizational Innovation; Substance Abuse Treatment Centers; Taurine; United States | 2010 |
Brief report: acamprosate in fragile X syndrome.
Topics: Acamprosate; Adolescent; Autistic Disorder; Communication; Comorbidity; Fragile X Syndrome; Humans; Male; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Taurine; Treatment Outcome; Verbal Behavior; Young Adult | 2010 |
Pharmacotherapies for alcoholism: the old and the new.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Disease Models, Animal; Disulfiram; Drug Design; Humans; Naltrexone; Narcotic Antagonists; Neuropeptides; Neuropharmacology; Neurotransmitter Agents; Receptors, Neurotransmitter; Taurine | 2010 |
Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Financing, Personal; Health Expenditures; Humans; Naltrexone; Patient Acceptance of Health Care; Prospective Studies; Randomized Controlled Trials as Topic; Taurine; United States | 2010 |
Pharmacotherapy of alcohol use disorders in the Veterans Health Administration.
Topics: Acamprosate; Administration, Oral; Adult; Age Factors; Alcohol Deterrents; Alcoholism; Ambulatory Care; Comorbidity; Delayed-Action Preparations; Disulfiram; Drug Therapy, Combination; Drug Utilization; Female; Humans; Injections, Intramuscular; Male; Mental Disorders; Middle Aged; Naltrexone; Selective Serotonin Reuptake Inhibitors; Sex Factors; Substance Abuse Treatment Centers; Taurine; United States; Veterans | 2010 |
The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.
Topics: Acamprosate; Accidents, Traffic; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Costs and Cost Analysis; Crime; Health Services; Humans; Naltrexone; Taurine | 2010 |
Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Alcohols; Atrial Natriuretic Factor; Female; GATA4 Transcription Factor; Gene Dosage; Genetic Association Studies; Genetic Variation; Humans; Linkage Disequilibrium; Male; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Randomized Controlled Trials as Topic; Recurrence; Risk; Taurine | 2011 |
Acamprosate determinations in plasma and cerebrospinal fluid after multiple dosing measured by liquid chromatography-mass spectroscopy: a pharmacokinetic study in healthy volunteers.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Male; Mass Spectrometry; Middle Aged; Reproducibility of Results; Taurine; Young Adult | 2010 |
Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Sex Characteristics; Taurine; Treatment Outcome | 2010 |
Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Corpus Striatum; Disease Models, Animal; Gene Expression Profiling; Glycine Plasma Membrane Transport Proteins; Male; Rats; Rats, Wistar; Secondary Prevention; Signal Transduction; Taurine; Tetrahydronaphthalenes | 2010 |
Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Female; Fructose; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Taurine; Temperance; Time Factors; Topiramate; Treatment Outcome | 2010 |
Acamprosate modulates alcohol-induced hippocampal NMDA receptors and brain microsomal Ca2+-ATPase but induces oxidative stress in rat.
Topics: Acamprosate; Alcohol Deterrents; Animals; Ascorbic Acid; beta Carotene; Calcium-Transporting ATPases; Glutathione Peroxidase; Hippocampus; Lipid Peroxidation; Male; Microsomes; Oxidative Stress; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Taurine; Vitamin E | 2010 |
Gambling on acamprosate: a case report.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents, Second-Generation; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Disruptive, Impulse Control, and Conduct Disorders; Drug Therapy, Combination; Female; Follow-Up Studies; Gambling; Humans; Middle Aged; Taurine; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Acamprosate reduces ethanol drinking behaviors and alters the metabolite profile in mice lacking ENT1.
Topics: Acamprosate; Alcohol Drinking; Animals; Equilibrative Nucleoside Transporter 1; Ethanol; Glutamic Acid; Male; Metabolome; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Nucleus Accumbens; Taurine; Up-Regulation | 2011 |
[Cochrane review about the effect of acamprosate].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Evidence-Based Medicine; Humans; Taurine; Treatment Outcome | 2010 |
A LC-MS analysis of acamprosate from human plasma: pharmacokinetic application.
Topics: Acamprosate; Adult; Alcohol Deterrents; Calibration; Chromatography, Liquid; Humans; Male; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Taurine; Time Factors | 2011 |
Comparison of healthcare utilization among patients treated with alcoholism medications.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Delayed-Action Preparations; Disulfiram; Female; Health Services; Health Status Indicators; Humans; Inpatients; Insurance Claim Review; Male; Middle Aged; Naltrexone; Narcotics; Propensity Score; Retrospective Studies; Taurine; United States | 2010 |
Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.
Topics: Acamprosate; Alcohol Deterrents; Buprenorphine; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Substance Abuse Treatment Centers; Substance-Related Disorders; Taurine; United States | 2011 |
Effectiveness of acamprosate in the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Secondary Prevention; Taurine; Treatment Outcome | 2011 |
Acamprosate attenuates cue-induced reinstatement of nicotine-seeking behavior in rats.
Topics: Acamprosate; Animals; Cues; Drug-Seeking Behavior; Male; Nicotine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Self Administration; Taurine | 2011 |
Acamprosate-responsive brain sites for suppression of ethanol intake and preference.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Brain; Circadian Rhythm; Drinking; Food Preferences; Hippocampus; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Models, Animal; Motor Activity; Nucleus Accumbens; Pedunculopontine Tegmental Nucleus; Period Circadian Proteins; Suprachiasmatic Nucleus; Taurine; Ventral Tegmental Area | 2011 |
Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Chi-Square Distribution; Databases, Factual; Disulfiram; Female; Health Care Costs; Health Services; Humans; Male; Naltrexone; Narcotic Antagonists; Propensity Score; Retrospective Studies; Statistics as Topic; Statistics, Nonparametric; Taurine; Treatment Outcome; United States | 2011 |
Circadian and acamprosate modulation of elevated ethanol drinking in mPer2 clock gene mutant mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Circadian Rhythm; Ethanol; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Period Circadian Proteins; Taurine | 2011 |
The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; beta-Alanine; Dopamine; Drug Tolerance; Glycine; Glycine Plasma Membrane Transport Proteins; Male; Nucleus Accumbens; Rats; Rats, Wistar; Taurine | 2012 |
Acamprosate modulates experimental autoimmune encephalomyelitis.
Topics: Acamprosate; Animals; Blood-Brain Barrier; Body Weight; Demyelinating Diseases; Encephalomyelitis, Autoimmune, Experimental; Female; Inflammation; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Pilot Projects; Taurine; Tumor Necrosis Factor-alpha | 2012 |
Pharmacogenetics of alcoholism: a clinical neuroscience perspective.
Topics: Acamprosate; Alcoholism; Alleles; Disulfiram; Genetic Markers; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Precision Medicine; Receptors, Opioid, mu; Serotonin Plasma Membrane Transport Proteins; Taurine | 2012 |
Influence of ionization source design on matrix effects during LC-ESI-MS/MS analysis.
Topics: Acamprosate; Chromatography, Liquid; Glycerylphosphorylcholine; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Taurine | 2012 |
Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1.
Topics: Acamprosate; Animals; Brain; Equilibrative Nucleoside Transporter 1; Ethanol; gamma-Aminobutyric Acid; Glutamic Acid; Magnetic Resonance Spectroscopy; Mice; Mice, Knockout; Phosphorylation; Substance Withdrawal Syndrome; Taurine | 2012 |
Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test.
Topics: Acamprosate; Animals; Antidepressive Agents; Benzamides; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Hindlimb Suspension; Immobility Response, Tonic; Male; Mice; Mice, Inbred C57BL; Motor Activity; N-Methylaspartate; Pyrazoles; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Taurine | 2012 |
Pharmacotherapy for adolescent alcohol use disorder.
Topics: Acamprosate; Adolescent; Alcohol-Related Disorders; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Central Nervous System Stimulants; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Disulfiram; Humans; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders; Taurine | 2012 |
Cocaine reverses the naltrexone-induced reduction in operant ethanol self-administration: the effects on immediate-early gene expression in the rat prefrontal cortex.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Carrier Proteins; Cocaine; Conditioning, Operant; Cyclooxygenase 2; Dose-Response Relationship, Drug; Gene Expression; Genes, fos; Genes, Immediate-Early; Homer Scaffolding Proteins; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Prefrontal Cortex; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Self Administration; Taurine | 2012 |
Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Attitude of Health Personnel; Disulfiram; Drug Utilization; Female; Formularies as Topic; Health Care Surveys; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Preference; Practice Guidelines as Topic; Practice Patterns, Physicians'; Qualitative Research; Taurine; United States; United States Department of Veterans Affairs; Veterans Health | 2013 |
Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Medication Adherence; Naltrexone; Patient Compliance; Patient Satisfaction; Taurine; Time Factors; Treatment Outcome | 2013 |
The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats.
Topics: Acamprosate; Amphetamine; Animals; Anxiety; Bridged Bicyclo Compounds; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Ligands; Male; Memantine; Pyridines; Rats; Receptors, Ionotropic Glutamate; Receptors, Metabotropic Glutamate; Substance Withdrawal Syndrome; Taurine; Thiazoles | 2013 |
Acamprosate suppresses ethanol-induced place preference in mice with ethanol physical dependence.
Topics: Acamprosate; Administration, Inhalation; Alcohol Deterrents; Alcoholism; Animals; Conditioning, Psychological; CREB-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Depression, Chemical; Dose-Response Relationship, Drug; Ethanol; Injections, Intraperitoneal; Limbic System; Male; Mice; Mice, Inbred Strains; Molecular Targeted Therapy; Signal Transduction; Taurine | 2013 |
[Electrophysiological study of acamprosate effects on frontal cortical neurons in rats].
Topics: Acamprosate; Action Potentials; Alcohol Deterrents; Animals; Ethanol; Frontal Lobe; Injections, Intraperitoneal; Injections, Intraventricular; Iontophoresis; Male; Microelectrodes; Neurons; Rats; Rats, Wistar; Taurine | 2013 |
Acamprosate {monocalcium bis(3-acetamidopropane-1-sulfonate)} reduces ethanol-drinking behavior in rats and glutamate-induced toxicity in ethanol-exposed primary rat cortical neuronal cultures.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Acamprosate; Alcohol Drinking; Animals; Behavior, Animal; Cells, Cultured; Cerebral Cortex; Dizocilpine Maleate; Ethanol; Glutamic Acid; Lactate Dehydrogenases; Male; Neurons; Neuroprotective Agents; Neurotoxins; Nifedipine; Pyridines; Rats; Rats, Wistar; Signal Transduction; Taurine | 2013 |
Acamprosate produces its anti-relapse effects via calcium.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Calcium; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Agents; Excitatory Postsynaptic Potentials; GABA Agents; Humans; In Vitro Techniques; Male; Membrane Potentials; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Taurine; Xenopus laevis | 2014 |
[Acamprosate has not proved to be efficient in the treatment of alcoholism in primary care medicine].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Primary Health Care; Taurine; Treatment Failure | 2013 |
Acamprosate: an alcoholism treatment that may not be what we thought.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Calcium; Humans; Male; Taurine | 2014 |
[Pharmacological profiles and clinical roles of acamprosate (Regtect(®) tablets 333 mg) for the maintenance of abstinence in alcohol-dependent patients].
Topics: Acamprosate; Alcoholism; Animals; Clinical Trials as Topic; Feeding Behavior; Humans; Tablets; Taurine | 2014 |
[Drug therapy supports reduction of alcohol consumption].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Meta-Analysis as Topic; Naltrexone; Taurine | 2014 |
Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate.
Topics: Acamprosate; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Female; Genetic Markers; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Remission Induction; Taurine; Time Factors; Treatment Outcome; Young Adult | 2014 |
Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker.
Topics: Acamprosate; Adolescent; Amyloid beta-Protein Precursor; Case-Control Studies; Child; Child Development Disorders, Pervasive; Child, Preschool; Female; Fragile X Syndrome; Humans; Male; Peptide Fragments; Pilot Projects; Taurine | 2014 |
Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids.
Topics: Acamprosate; Analysis of Variance; Animals; Antidiuretic Hormone Receptor Antagonists; Bupropion; Dose-Response Relationship, Drug; Fructose; Indoles; Male; Motor Activity; Naltrexone; Nicotine; Nicotinic Agonists; Pyrrolidines; Rats, Wistar; Taurine; Tobacco Use Cessation Devices; Topiramate | 2016 |
Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT.
Topics: Acamprosate; Age Factors; Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Combined Modality Therapy; Controlled Clinical Trials as Topic; Decision Trees; gamma-Glutamyltransferase; Germany; Goals; Humans; Logistic Models; Middle Aged; Naltrexone; Predictive Value of Tests; Randomized Controlled Trials as Topic; Reproducibility of Results; Taurine; Time Factors; Treatment Outcome; United States | 2014 |
Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: a retrospective study.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Bipolar Disorder; Female; Humans; Italy; Male; Middle Aged; Retrospective Studies; Taurine; Young Adult | 2014 |
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy.
Topics: Acamprosate; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Apoptosis; Baclofen; Cells, Cultured; Disease Models, Animal; Drug Repositioning; Drug Synergism; Female; Humans; Male; Mice; Mice, Transgenic; Neurons; Neuroprotective Agents; Peptide Fragments; Rats; Rats, Wistar; Signal Transduction; Taurine | 2015 |
Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Animals; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Eating; Ethanol; Male; Naltrexone; Pregnanolone; Rats; Rats, Long-Evans; Self Administration; Taurine | 2015 |
[Acamprosate and naltrexone: similar efficacy for relapse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Recurrence; Taurine | 2014 |
Effects of acamprosate on attentional set-shifting and cellular function in the prefrontal cortex of chronic alcohol-exposed mice.
Topics: Acamprosate; Action Potentials; Alcohol Drinking; Alcoholism; Animals; Attention; Ethanol; Membrane Potentials; Mice; Prefrontal Cortex; Pyramidal Cells; Synaptic Transmission; Taurine | 2015 |
Medicaid coverage of medications to treat alcohol and opioid dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Buprenorphine, Naloxone Drug Combination; Humans; Insurance Coverage; Medicaid; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Taurine; United States | 2015 |
Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy.
Topics: Acamprosate; Alcohol Deterrents; Alcoholics; Alcoholism; Baclofen; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver Cirrhosis; Liver Neoplasms; Pyridoxine; Pyrrolidonecarboxylic Acid; Risk Factors; Taurine | 2016 |
The indirect NMDAR antagonist acamprosate induces postischemic neurologic recovery associated with sustained neuroprotection and neuroregeneration.
Topics: Acamprosate; Animals; Blood-Brain Barrier; Brain Ischemia; Calpain; Enzyme Activation; Interleukin-12 Subunit p35; JNK Mitogen-Activated Protein Kinases; Male; Mice; Neovascularization, Physiologic; Nerve Regeneration; Neuroprotective Agents; Oxidative Stress; Receptors, N-Methyl-D-Aspartate; Recovery of Function; STAT6 Transcription Factor; Taurine | 2015 |
Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biomarkers; Glutamic Acid; Humans; Taurine; Treatment Outcome | 2015 |
Factors Affecting Ethanol-Induced Conditioned Place Preference and Locomotor Sensitization in Mice.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Association Learning; Conditioning, Psychological; Ethanol; Locomotion; Male; Mice, Inbred DBA; Motor Activity; Reward; Risk Factors; Taurine | 2015 |
Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.
Topics: Acamprosate; Animals; Baclofen; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drug Therapy, Combination; Female; Male; Nerve Degeneration; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Taurine | 2015 |
The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Humans; Insurance Carriers; Longitudinal Studies; Medicaid; Patient Protection and Affordable Care Act; Substance Abuse Treatment Centers; Taurine; United States | 2016 |
Association between a brief alcohol craving measure and drinking in the following week.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Odds Ratio; Randomized Controlled Trials as Topic; Taurine; United States | 2016 |
Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice.
Topics: Acamprosate; Alcohol Drinking; Animals; Anxiety; Citalopram; Depression; Drug Therapy, Combination; Male; Mice; Stress, Psychological; Taurine | 2016 |
Access to Addiction Pharmacotherapy in Private Health Plans.
Topics: Acamprosate; Buprenorphine; Cost Sharing; Evidence-Based Practice; Formularies as Topic; Health Services Accessibility; Humans; Insurance, Health; Naltrexone; Substance-Related Disorders; Surveys and Questionnaires; Taurine; United States | 2016 |
National trends in alcohol pharmacotherapy: Findings from an Australian claims database.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Australia; Drug Administration Schedule; Female; Guideline Adherence; Humans; Insurance Claim Review; Male; Naltrexone; Patient Compliance; Retrospective Studies; Taurine; Temperance | 2016 |
Pharmacotherapy for Adults with Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2016 |
Marketing Status and Perceived Efficacy of Drugs for Supporting Abstinence and Reducing Alcohol Intake in Alcohol Use Disorders: A Survey among European Federation of Addiction Societies in Europe.
Topics: Acamprosate; Alcohol Abstinence; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Europe; Humans; Marketing; Naltrexone; Narcotic Antagonists; Perception; Practice Guidelines as Topic; Societies, Medical; Surveys and Questionnaires; Taurine; Treatment Outcome | 2016 |
Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Female; Fructose; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Taurine; Topiramate; United States; United States Department of Veterans Affairs; Veterans; Young Adult | 2016 |
A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Missouri; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Psychotherapy; Taurine | 2016 |
Anterior Cingulate Glutamate Is Reduced by Acamprosate Treatment in Patients With Alcohol Dependence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Female; Glutamic Acid; Gyrus Cinguli; Humans; Male; Middle Aged; Proton Magnetic Resonance Spectroscopy; Taurine; Treatment Outcome; Young Adult | 2016 |
Cannabis use during treatment for alcohol use disorders predicts alcohol treatment outcomes.
Topics: Acamprosate; Adult; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Marijuana Use; Middle Aged; Naltrexone; Narcotic Antagonists; Prognosis; Randomized Controlled Trials as Topic; Taurine; Treatment Outcome | 2017 |
Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence.
Topics: Acamprosate; Adolescent; Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcoholism; Australia; Drug Prescriptions; Female; Health Services Accessibility; Healthcare Disparities; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Retrospective Studies; Social Class; Taurine; Vulnerable Populations; Young Adult | 2017 |
Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Cohort Studies; Disulfiram; Female; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Primary Health Care; Sex Factors; Socioeconomic Factors; Taurine; Time Factors; Treatment Outcome; United Kingdom; Young Adult | 2017 |
Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Interviews as Topic; Male; Naltrexone; Residential Treatment; Taurine; United States; United States Department of Veterans Affairs; Veterans | 2017 |
First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Female; Humans; Insurance, Pharmaceutical Services; Male; Middle Aged; Naltrexone; Ontario; Population Surveillance; Retrospective Studies; Single-Payer System; Taurine; Young Adult | 2017 |
Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Drinking Behavior; Female; Humans; Male; Naltrexone; Risk; Taurine; Treatment Outcome; United Kingdom; United States | 2017 |
More Treatments on Deck for Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline | 2017 |
High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking.
Topics: Acamprosate; Animals; Baclofen; Binge Drinking; Darkness; Disease Models, Animal; Ethanol; Female; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Naltrexone; Taurine | 2017 |
Acamprosate rescues neuronal defects in the Drosophila model of Fragile X Syndrome.
Topics: Acamprosate; Animals; Animals, Genetically Modified; Behavior, Animal; Calbindins; Disease Models, Animal; Dose-Response Relationship, Drug; Drosophila melanogaster; Drosophila Proteins; Fragile X Mental Retardation Protein; Fragile X Syndrome; Larva; Locomotion; Neuromuscular Junction; RNA, Messenger; Taurine | 2018 |
Acamprosate Protects Against Adjuvant-Induced Arthritis in Rats via Blocking the ERK/MAPK and NF-κB Signaling Pathway.
Topics: Acamprosate; Animals; Arthritis, Experimental; Inflammation; Male; MAP Kinase Signaling System; NF-kappa B; Osteoarthritis; Protective Agents; Rats; Rats, Wistar; Signal Transduction; Taurine | 2018 |
Use of Medications for the Treatment of Alcohol Dependence: A Retrospective Study Conducted in 2011-2012.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Retrospective Studies; Taurine | 2021 |
In recently detoxified alcohol-dependent adults, acamprosate increases abstinence maintenance and reduces dropout.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Ethanol; Humans; Taurine | 2021 |
Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Ethanol; Genome-Wide Association Study; Humans; Taurine | 2022 |
The effects of acamprosate on prefrontal cortical function are mimicked by CaCl2 and they are influenced by the history of alcohol exposure.
Topics: Acamprosate; Animals; Calcium; Calcium Chloride; Ethanol; Mice; Prefrontal Cortex; Recurrence; Taurine | 2022 |
Sodium acamprosate and calcium exert additive effects on nucleus accumbens dopamine in the rat.
Topics: Acamprosate; Animals; Calcium; Calcium Chloride; Dopamine; Male; Microdialysis; Nucleus Accumbens; Rats; Rats, Wistar; Receptors, Glycine; Sodium; Taurine | 2022 |
Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Female; Humans; Male; Naltrexone; Ontario; Taurine | 2023 |